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Abstract 
 
Familial hypercholesterolemia (FH) is a genetic disorder of severely elevated low-
density lipoprotein (LDL) cholesterol that is widely underdiagnosed and undertreated. To 
improve the identification of FH and initiate timely and appropriate treatment strategies, 
genetic testing is becoming increasingly offered worldwide as a central part of diagnosis. I 
describe three main ways providing a genetic diagnosis in FH can be improved. First, next-
generation sequencing (NGS)-based approaches can be used to reliably identify large-scale 
variant types known as copy number variations (CNVs) in the LDL receptor gene (LDLR); 
second, NGS methodology can be further applied to extend CNV screening to additional FH-
associated genes, which have remained uninvestigated but may harbor novel causative 
variation; and third, the interpretation of variants identified during the course of genetic 
testing can be improved with the establishment of an open-source database containing 
variants identified in FH patients worldwide.  
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Chapter 1 – Introduction 
 
 
 LDL cholesterol 
 
Cholesterol is an important biological molecule that has an essential role in cell 
membrane structure, and as a precursor for the biosynthesis of vitamin D, bile acid, and 
steroid hormones. Only ~ one-fifth of cholesterol in humans originates from dietary 
intake; the majority of cholesterol is synthesized by the liver (Brown & Goldstein, 1986).  
As an insoluble lipid, cholesterol requires two main types of lipoproteins for 
transport through blood plasma: high-density lipoproteins (HDL) and low-density 
lipoproteins (LDL) (Hegele, 2009). Cholesterol transported within HDL particles (HDL-
C) is often referred to as “good” cholesterol, as it associates with the movement of 
cholesterol from peripheral tissue to the liver, where it can be safely disposed of (Lagor 
& Millar, 2010). LDL cholesterol (LDL-C) however, is often referred to as “bad” 
cholesterol, as it associates with cholesterol transport from the liver to peripheral tissues, 
where it is deposited (Lagor & Millar, 2010). These colloquial expressions “bad” and 
“good” thus refer to the direction of cholesterol transport, rather than the cholesterol 
itself, which is qualitatively the same. 
When LDL-C levels are excessively elevated, the deposition of cholesterol into 
peripheral tissues, such as the arterial walls, can become accelerated (Hegele, 1997). In 
the arterial walls, excess cholesterol is oxidatively modified by macrophages, initiating 
inflammation of vasculature and formation of atherosclerotic plaques (Hegele, 1997). 
Atherosclerosis causes a narrowing of the arteries, and is a major risk factor for the 
development of cardiovascular diseases (CVDs), such as coronary heart disease (CHD; 
restricted blood flow to the heart) and cerebrovascular disease (restricted blood flow to 
the brain) (Berenson et al., 1998). Alarmingly, for every mmol/L increment of raised 
LDL-C, the risk of CHD has been shown to increase by ~40% (Sharrett et al., 2001).  
LDL-C homeostasis is primarily governed via regulation of the LDL receptor 
(LDLR) protein, and is explained briefly below in Figure 1.1. 
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Figure 1.1. LDL cholesterol homeostasis via the LDL receptor. When intracellular 
cholesterol levels are low, expression of the LDLR gene (LDLR) is upregulated by the 
sterol regulator element binding protein-2 (SREBP-2) transcription factor (Horton et al., 
2002). LDLR mRNA is translated in the endoplasmic reticulum and matures in the Golgi 
apparatus before reaching the cell surface. On the cell surface, LDLRs concentrate in 
clathrin-coated pits; while LDLRs are found on most cells they are most highly abundant 
on hepatocytes. Apolipoprotein B100 (Apo B) is the major apolipoprotein of the LDL 
particle. Embedded in LDL’s outer phospholipid layer, Apo B is the ligand for the LDLR 
(Chatterton et al., 1995). Following binding of the LDL particle to LDLR, the receptor-
ligand complex is internalized by receptor-mediated endocytosis (Brown & Goldstein, 
1979). The intracellular LDLR adapter protein 1 (LDLRAP1) interacts with a NPXY 
motif within the cytoplasmic tail of  LDLR to facilitate this internalization at clathrin-
coated pits (Chen, Goldstein, & Brown, 1990; Garcia et al., 2001). Clathrin-coated 
vesicles containing the LDLR-LDL complex bud off the cell membrane and then fuse to 
form the early endosome (Anderson, Brown, & Goldstein, 1977). In the late endosome, a 
pH change leads to the dissociation of the LDLR-LDL complex; the LDL particle is 
delivered to the lysosome where the protein component is hydrolyzed, liberating the 
cholesterol for cellular use (Goldstein et al., 1975). The LDLR is normally recycled back 
to the cell surface to bind more circulating LDL particles, initiating another cycle of 
receptor-mediated endocytosis; the LDLR can be recycled as many as 100 times (Brown 
et al., 1983). In response to high intracellular cholesterol, expression of LDLR is 
downregulated by inhibition of SREBP-2, and LDLRs begin to get degraded in the late 
endosome rather than recycled to the cell surface. Degradation of LDLR is mediated by 
proprotein convertase subtilisin-kexin 9 (PCSK9). PCSK9 exists both intracellularly and 
extracellularly, and in both cases directs the LDLR to endosome (Zhang et al., 2007). In 
the endosome PCSK9 disrupts the pH-induced dissociation of the LDLR-LDL complex 
and the complex progresses through to the lysosome where it is degraded. Interestingly, 
PCSK9 expression is also upregulated by the SREBP-2 transcription factor, likely to 
maintain tight regulatory control of plasma LDL-C. (Figure adapted from (Berberich & 
Hegele, 2018)). 
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LDL-C levels (normal: 2-3 mmol/L) are influenced by a range of both 
environmental and genetic determinants, responsible for the right-skewed, normal 
distribution within the population (Hegele, 2009). For extreme LDL-C phenotypes 
however, a more prominent genetic influence is expected (Hegele, 2009). Familial 
hypercholesterolemia (FH) is defined as the heritable condition of elevated LDL-C, 
characterized by LDL-C concentrations within the 95th percentile adjusted for age and 
sex (~ ≥ 5 mmol/L in adults).   
FH as a monogenic disorder has been historically well characterized in the 
literature. For those with monogenic FH, extreme LDL-C phenotypes can be explained 
by the presence of single-gene, large-effect DNA variants, capable of causing severe 
disruptions to LDL-C homeostasis (Rader et al., 2003).  
 
 
 Genetic basis of familial hypercholesterolemia 
 
 
1.2.1 LDLR 
 
More than 90% of genetically defined FH cases are due to autosomal codominant 
variants in the LDLR gene. Extensive study of LDLR in FH patients has led to the 
identification of  >1700 unique variants prior to 2018 (Bourbon et al., 2017). Variants 
causing a loss of function in the encoded protein are causative for FH; such variants have 
been described throughout all 18 exons of LDLR and include single nucleotide changes, 
such as missense variants altering a single amino acid residue, nonsense variants 
introducing a premature stop codon, and splicing variants; small insertion/deletion (indel) 
variants which remove/add amino acids, or alter the reading frame (frameshift); and large 
indels or copy number variations spanning one or multiple exons (see below). The 
relative proportions of LDLR variant types identified in FH patients are illustrated in 
Figure 1.2. 
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Figure 1.2. Relative proportions of LDLR variant types identified in FH patients. 
 
 
 
1.2.1.1 LDLR copy number variations 
 
Copy number variations (CNVs) are a form of quantitative structural 
rearrangement that include deletions, duplications, and higher order amplifications of 
DNA sequence larger than 50 bases in size (Redon et al., 2006).  
The LDLR locus appears to be prone to acquiring CNVs across evolutionary time. 
The locus contains a particularly high abundance of Alu sequences - the most prevalent 
repeat element in the genome - making it especially susceptible to CNV mutagenesis via 
mechanisms associated with faulty DNA repair, replication, and recombination, such as 
non-homologous end joining (Goldmann et al., 2010), replication fork stalling and 
template switching (Horsthemke et al., 1987), and non-allelic homologous recombination 
(Lehrman et al., 1985), respectively. 
Molecular biological studies over the past three decades indicate a remarkably 
large number of naturally occurring LDLR CNVs in FH probands and families: 56 unique 
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deletions and 27 unique duplications (Figure 1.3) prior to 2018 (Iacocca & Hegele, 
2018). Of the 98 Alu repeats in LDLR, 95 are within the introns, and account for 85% of 
the intronic sequence outside of splice-site junctions (Amsellem et al., 2002), explaining 
why essentially all LDLR CNVs so far described in FH patients are in-frame, whole-exon 
events (i.e. breakpoints located within the introns). Despite the comparable number of 
unique deletions and duplications reported among the literature, in any single FH cohort 
the large majority (>90%) of LDLR CNV events detected have been heterozygous 
deletions, often involving multiple exons (Bertolini et al., 2017; Jannes et al., 2015; 
Miyake et al., 2009; Taylor et al., 2009).  
 
 
 
 
 
Figure 1.3. LDLR CNVs described in patients with FH. The LDLR gene structure and its 
18 exons (E#) are shown from left to right (5’ to 3’).  
 
7 
 
1.2.2 APOB 
 
Autosomal codominant variants in APOB underlie 5-8% of FH cases. FH-causing APOB 
variants encode a secreted Apo B that is still available for the formation of the LDL 
particle (more specifically its very-LDL (VLDL) particle precursor), but binds 
defectively to the LDL receptor. Known LDL receptor binding domains are located in 
APOB exons 26 and 29 (Kriško & Etchebest, 2007). Although there have been numerous 
protein-altering variants located in APOB exons 26 and 29 described in FH patients, the 
majority of APOB cases are due to a single amino acid substitution of arginine for 
glutamine at residue 3527 [exon 26; p.(Arg3527Gln)], shown to significantly reduce the 
affinity of Apo B for the LDLR (Innerarity et al., 1987). Interestingly, recent evidence 
has begun to suggest causative FH variants may also exist elsewhere throughout the 
APOB gene, although the exact mechanisms of impaired LDLR binding due to such 
variants are still mostly unclear (Alves et al., 2014). Causative variant types so far 
identified in APOB include frameshift, missense, nonsense, and splicing (Chora et al., 
2018). Importantly, null/deleterious variants in APOB which prevent VLDL/LDL particle 
formation are known to cause hypocholesterolemia – i.e. low LDL-C. 
 
1.2.3 PCSK9 
 
Autosomal codominant variants in PCSK9 underlie ~1% of FH cases. In PCSK9, gain-of-
function (GOF) variants - which lead to increased degradation of the LDLR – are 
causative for FH. Disease-causing GOF variants have been described throughout all 
domains of the encoded protein, and have so far included a 5’ untranslated region (UTR) 
substitution, missense, splicing, and small indel variant types (Dron & Hegele, 2017). 
Importantly, variants causing a loss of function in PCSK9 reduce LDLR degradation and 
are known to cause hypocholesterolemia.  
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1.2.4 LDLRAP1 
 
Unlike LDLR, APOB, and PCSK9, variants in LDLRAP1 are recessive - i.e. an individual 
must carry two mutant alleles to exhibit an FH phenotype; autosomal recessive variants 
in LDLRAP1 underlie <1% of FH cases, and are a form of homozygous FH (HoFH). Loss 
of function variants which reduce the capacity of LDLRAP1 to interact with the 
cytoplasmic tail of LDLR in clathrin-coated pits are causative of FH (Wijers et al., 2015). 
Causative variant types so far described in LDLRAP1 include frameshift, missense, 
nonsense, and splicing. 
 
1.2.5 Additional FH-associated genes 
 
Systematic studies of clinical FH patients with no apparent causative variants in LDLR, 
APOB,  PCSK9 (or LDLRAP1) have revealed a handful of ultra-rare variants in other 
genes that may occasionally cause FH or an FH-like phenotype (i.e. phenocopies). These 
include autosomal dominant variants in APOE and STAP1, and autosomal recessive 
variants in LIPA and ABCG5/8 . 
 APOE encodes apolipoprotein E (Apo E). In 2012, Marduel et al. identified an in-
frame deletion (c.500_502delTCC) resulting in the elimination of a leucine residue at 
position 167 (p.Leu167del) in APOE  in a large French family of 14 members with clear 
autosomal dominant FH. This variant cosegregated with affected status in this index 
family, and also in two other families identified. Apo E is an apolipoprotein present on 
VLDL particles; functional evidence suggested that cellular VLDL uptake is increased by 
the p.Leu167del variant, leading to increased intracellular cholesterol and thus a down 
regulation of LDLR transcription (Cenarro et al., 2016). This down regulation of LDLR 
was thus the plausible explanation of isolated high LDL-C in FH. To date, this is the only 
FH-causing APOE variant to be reported.  
 STAP1 encodes signal transducer adapter protein 1 (STAP1). In 2014, Fouchier et 
al. described STAP1 as a 5th putative locus for autosomal dominant FH. In 400 FH 
patients with no LDLR/APOB/PCSK9 causal variants they combined parametric linkage 
analysis with whole-exome sequencing and identified four independent missense variants 
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(p.Glu97Asp, p.Leu69Ser, p.Ile71Thr, and p.Asp207Asn) in STAP1 to associate with 
FH/high LDL-C in five families. STAP1 has been suggested to act downstream of 
receptor tyrosine kinases (Masuhara et al., 2000), however, the function of STAP1, 
especially in relation to LDL-C, is still unknown. Association of STAP1 to FH is still 
only supported by clinical data and cosegregation analysis in these five index case 
families, rather than by mechanistic evidence. 
 LIPA encodes lysosomal acid lipase (LAL). Recessive variants causing a loss of 
function in LIPA result in LAL deficiency (LALD). LAL is an enzyme that catalyzes the 
hydrolytic breakdown of lipids such as cholesteryl esters and triglycerides in the 
lysosome; the accumulation of intracellular lipids in LALD patients leads to toxic buildup 
of fats in multiple tissues (Goldstein et al., 1975). The severity of the disorder depends on 
the residual function of the mutated LAL; those with no enzymatic function develop 
severe multi-organ failure and rarely survive beyond the first year of life (Burton, 
Deegan, et al., 2015). Most LALD patients, however, experience signs and symptoms 
beginning in mid-childhood, and some later into adulthood. In these “later-onset” LALD 
cases, disease is still life-threatening and often accompanied by liver disease and high 
LDL-C levels (Burton, Deegan, et al., 2015). In some cases, patients with LALD may 
present clinically as FH (often HoFH) (Chora et al., 2017; Sjouke et al., 2016). The 
prevalence of LALD is still largely unknown, although most estimates suggest an 
incidence of  ~1 in 40,000 to 1 in 300,000 (Reiner et al., 2014).  
 ABCG5 and ABCG8 encode ATP-binding cassette sub-family G member 5 and 8, 
respectively. These proteins form an obligate heterodimer; recessive variants causing a 
loss of function in ABCG5/8 result in sitosterolemia (Tada et al., 2018). Found mostly on 
hepatic and intestinal cells, the ABCG5/8 transporter controls the efflux of dietary plant 
sterols (lipids from vegetable oils, nuts, avocados, etc.), and to a lesser extent dietary 
cholesterol; those with sitosterolemia have increased intestinal absorption and decreased 
biliary excretion of sterols. Although most patients with sitosterolemia have only mild to 
moderately elevated LDL-C levels, some, particularly children, may present clinically as 
HoFH, with xanthomas (cholesterol deposits within the skin; common in HoFH) and 
premature atherosclerosis (Brinton et al., 2018; Tada et al., 2018). Sitosterolemia is rare, 
with an estimated prevalence of ~1 in 50,000 to 1 in 200,000 (Yoo, 2016).  
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 Together, causative variants in APOE, STAP1, LIPA, and ABCG5/8 have been 
implicated in <1% of FH cases. However, because identifying a causative variant in one 
of these genes can help explain the FH phenotype in patients negative for LDLR, APOB, 
PCSK9, and LDLRAP1 variants, and potentially impact treatment (see below), screening 
for them in a diagnostic context is warranted.  
 
1.2.6 Polygenic hypercholesterolemia 
 
Despite the progress in defining single-gene causes of FH, a substantial proportion (~20-
40%) of patients with the FH phenotype validated by clinical criteria have no obvious 
disease-causing variant (Humphries et al., 2006; Soutar & Naoumova, 2007). Reasons for 
this include possible rare variants in novel genes, the confounding effects of gene-by-
environment or gene-by-gene interactions, epigenetic mechanisms, and variant types that 
are missed by current technologies. But most importantly, polygenic inheritance explains 
phenotypic FH in many individuals without pathological monogenic variants (Talmud et 
al., 2013). Some of these patients carry a disproportionately high burden of common 
LDL-C raising alleles, possibly in complex interaction with environment to manifest in 
the clinical phenotype; a polygenic basis may explain 20% or more of patients with 
phenotypic FH (Wang et al., 2016).  
 
 
 Prevalence of FH, associated risks, and treatment 
 
Heterozygous FH (HeFH; often just referred to as FH), which can be caused by 
heterozygous variants in LDLR, APOB, PCSK9, and APOE (and possibly STAP1), is 
estimated to affect 1 in 250 individuals in the general population (Akioyamen et al., 
2017), making it among the most common known monogenic disorders. Further, the 
prevalence in certain founder populations is even higher, such as ~1 in 200 in French 
Canadians, ~1 in 165 in Tunisians, ~1 in 85 in Christian Lebanese, and ~1 in 72 in South 
African Afrikaners (Austin et al., 2004). Homozygous FH (HoFH; often specified as so) 
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is far more rare, with an estimated incidence of ~1 in 300,000 (Sjouke et al., 2015). 
HoFH can be caused by bi-allelic variants in LDLRAP1, bi-allelic variants in LDLR 
(either "simple homozygosity" for the identical variant or "compound heterozygosity" for 
two different variants), or heterozygous variants within two of the known autosomal 
dominant FH genes (LDLR, APOB, PCSK9, APOE, and possibly STAP1) - referred to as 
"double heterozygosity".  
 In HeFH, baseline LDL-C typically ranges from ~5 to 10 mmol/L in adults. If left 
untreated, atherosclerotic cardiovascular disease (CVD) onset occurs often by age 55 in 
men and 60 in women, with half of all affected men and 15% of women suffering from 
myocardial infarction (MI) before these ages (Nordestgaard et al., 2013). In HoFH, 
baseline LDL-C ranges from ~12 to upwards of >20 mmol/L. HoFH individuals can 
develop severe CVD and physical findings beginning in childhood; they can also suffer 
MI as adolescents if untreated (Cuchel et al., 2014). Given that those with FH are 
exposed to severely elevated LDL-C since birth, it is critical to identify and intensively 
treat affected individuals as early as possible (Wiegman et al., 2015).  
 Several lipid-lowering medications are available for treatment of FH, of which 
statins are the most widely used. Statins inhibit HMG-CoA (5-hydroxy-3-methylglutaryl-
coenzyme A) reductase, the rate-limiting enzyme in cholesterol synthesis; this leads to an 
upregulation of LDLR gene expression by SREBP-2 and thus an increased capacity to 
remove LDL-C from the bloodstream (Endo, 2010). The effectiveness of statins has been 
supported in a number of long term clinical trials of over 50,000 individuals, shown to 
both reduce LDL-C levels (25-35%) and CVD risk (24-37%) (Marks et al., 2003; Stroes, 
2005). In patients that do not reach the desired LDL-C targets (often 50% reduction from 
baseline or <2 mmol/L, if possible) on statin monotherapy alone, additional 
pharmacological agents may be administered. Most often, this includes ezetimibe; 
ezetimibe acts by decreasing cholesterol absorption in the small intestine (i.e. dietary 
cholesterol) (Burnett & Huff, 2006). Recently, monoclonal antibody inhibitors of PCSK9 
– alirocumab and evolocumab – have become approved for the care of FH patients. 
Inhibition of PCSK9 reduces LDLR degradation (see Figure 1.1 above). PCSK9 
inhibitors are potent in reducing LDL-C levels, and can be especially effective in patients 
who have not reached desired LDL-C targets despite maximum dose of statin therapy, 
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and/or in those who have adverse side effects to statins. In a study of 735 HeFH patients, 
alirocumab reduced baseline LDL-C levels 50-60% (Kastelein et al., 2015), while 
evolocumab reduced LDL-C levels by an average of 53.6% in 440 HeFH patients across 
two clinical trials (Hovingh et al., 2017) .  
 Using the above prevalence figures, there are an estimated ~34 million individuals 
affected with FH worldwide. Early diagnosis and timely treatment can normalize life 
expectancy in most patients with FH (Koch et al., 2012; Versmissen et al., 2008). 
However, despite the fact that FH is eminently treatable, <10% of those affected 
worldwide have been diagnosed, and <1% have been diagnosed in most countries 
(Nordestgaard et al., 2013). FH is thus considered to be severely underdiagnosed and 
undertreated. 
 
 
 Is there a need for a genetic diagnosis in FH? 
 
The diagnostic criteria for FH have evolved to reflect our increased understanding of the 
genetic determinants of high LDL-C. Both the widely used Dutch Lipid Clinic Network 
(DLCN) and Simon Broome Register (SBR) criteria use scoring systems that weigh 
variables such as degree of LDL-C elevation, presence of physical signs of cholesterol 
deposition, and family history of high LDL-C and/or premature coronary heart disease 
(CHD), and presence of a causative variant in LDLR, APOB, or PCSK9. Depending on a 
patient's score, the FH diagnosis is ranked as "definite", "probable" or "possible"; 
importantly a positive DNA result yields the highest number of points, and can be 
sufficient on its own to invoke a diagnosis of "definite FH". Both sets of criteria are 
shown in Table 1.1.  
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Table 1.1. Commonly used criteria for the clinical diagnosis of FH. 
 
Simon Broome Register Criteria Dutch Lipid Clinic Network Criteria 
 
(A)  
Family history of myocardial infarction in 1st 
degree relative <60 years, or 2nd degree relative 
<50 years 
 
 
(B)  
Family history of TC >7.5 mmol/L  
or LDL-C >4.9 mmol/L in 1st or 2nd degree relative 
 
 
(C)  
Adult: TC >7.5 mmol/L or LDL-C >4.9 mmol/L  
Child (<16 years): TC >6.7 mmol/L  
or LDL-C >4.0 mmol/L 
 
 
(D)  
Tendon xanthoma in patient or 1st degree relative 
 
 
(E)  
Causative mutation in LDLR, APOB, or PCSK9 
 
1. Family History 
(i) 1st degree relative with premature (<55 years 
men, <60 years women) CHD (1 point) 
 
(ii) 1st degree relative with LDL-C >95th percentile 
by age/gender for country (1 point) 
 
(iii) 1st degree relative with tendon xanthoma 
and/or premature corneal arcus (2 points) 
 
(iv) Children <18 years with LDL-C >95th 
percentile by age/gender for country (2 points) 
 
2. Clinical History 
(i) Premature CHD (2 points) 
 
(ii) Premature cerebral or peripheral vascular 
disease (1 point) 
 
3. Physical Signs 
(i) Tendon xanthoma (6 points) 
 
(ii) Corneal arcus in person <45 years (4 points) 
 
4. LDL-C Level 
(i) LDL-C >8.5 mmol/L (8 points) 
 
(ii) LDL-C 6.5-8.4 mmol/L (5 points) 
 
(iii) LDL-C 5.0-6.4 mmol/L (3 points) 
 
(iv) LDL-C 4.0-4.9 mmol/L (1 point) 
 
5. DNA Analysis 
(i) Causative variant in LDLR, APOB, or PCSK9 
(8 points) 
 
 
Diagnosis: Definite FH requires C and D, or E 
                  Probable FH requires A and C, or B     
                  and C  
 
 
 
Diagnosis: Definite FH > 8 points 
                  Probable FH 6-8 points 
                  Possible FH 3-5 points 
 
CHD, coronary heart disease. 
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It is noteworthy that the clinical features, especially the physical findings, have 
assumed less diagnostic importance in more recent times. Secular trends in diet and 
lifestyle, and widespread use of lipid-lowering therapies have altered the once "classical" 
FH presentation (Kindt, Mata, & Knowles, 2017). The physical findings of tendon 
xanthomas and corneal arcus, which carry weight in both SBR and DLCN criteria scoring 
(see above), are encountered far less frequently today than 20 years ago. For instance, of 
the 2752 patients in the SAFEHEART (Spanish Familial Hypercholesterolemia Cohort 
Study) registry with molecularly defined FH, only 14% had tendon xanthomas (De Isla et 
al., 2016), similar to findings in US (Degoma et al., 2016) and Canadian FH registries. 
Improvements in diet, lifestyle and medication use have also potentially delayed or 
attenuated CHD development in FH families. Furthermore, family history - which also 
carries weight in both scoring systems - may be unreliable or unascertainable in certain 
communities or jurisdictions. Thus, a “definite” FH diagnosis by current criteria is 
becoming increasingly reliant upon the identification of a causal DNA variant. Finally, 
the DLCN and SBR criteria are frequently used to determine eligibility for clinical trials 
and for insurance coverage; the increased prominence of genetic diagnosis in these 
criteria thus has further implications for drug development and coverage for clinical use.  
Despite arguments favoring genetic diagnosis in FH, such findings must be 
interpreted within the entire clinical context for an individual patient or family, including 
the degree of LDL-C elevation. Nonetheless, documenting a causal variant is increasingly 
becoming a central element in FH diagnosis.  
 
1.4.1 The importance of cascade screening 
 
Another strategic reason to obtain a genetic diagnosis of FH is to initiate detection of 
affected family members. Identifying the causal variant in the index case simplifies the 
screening process, making it more cost-effective, as the specific variant can then be 
directly genotyped using a less expensive dedicated method (Knowles et al., 2017); the 
lipid profile can sometimes serve as a surrogate for a DNA test when the latter is not 
available (Williams et al., 1993). The strategy of ascertaining cases based on their 
familial relationship with a confirmed index case is called "cascade screening". First, 
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second, and third degree relatives of an index (He)FH case with a causal variant have, 
respectively, a 50%, 25%, and 12.5% chance of also having FH. Cascade screening has 
been repeatedly shown to markedly improve rates of diagnosis and treatment for FH 
(Hopkins, 2017). The most striking example is from the Netherlands, where cascade 
screening has led to >28,000 additional cases being identified, improving the rate of 
diagnosis to an estimated ~70% of the total FH population, which is by far the highest of 
any country (Nordestgaard et al., 2013). The impact of early diagnosis and treatment with 
statins of HeFH in the Netherlands bends the survival curve towards a normal trajectory 
(Koch et al., 2012); cascade screening has played a key role in this successful national 
prevention strategy. 
In Australia and Brazil, cascade screening has also proven to be effective; each 
index case typically leads to the identification of FH in two affected relatives (Bell et al., 
2015; Jannes et al., 2015). In addition, and perhaps most importantly, cascade screening 
allows for pre-symptomatic diagnosis at a young age. Although family screening can be 
undertaken using non-genetic phenotypic criteria alone, this approach can be inadequate 
since a significant proportion of affected relatives have LDL-C levels that fall below the 
strict diagnostic cut point (often LDL-C >90th percentile) (Leren et al., 2008). However, 
because their genotype predisposes to higher lifetime exposure to elevated LDL-C and 
CVD, causal-variant carriers who are related to an index FH case should be considered 
for lipid-lowering intervention as a preventative measure.  
 
1.4.2 Does knowledge of the genotype impact upon clinical 
management? 
 
It might be argued that irrespective of genotype, LDL-C level itself is the ultimate 
determinant of CVD risk and should primarily direct the timing and intensity of 
intervention (Hopkins, 2017). However, because FH is genetically heterogeneous, there 
are definitely instances when knowing the genotype can affect treatment decisions. The 
most definitive examples are HoFH individuals, whose disease course and treatment 
needs are dramatically different from those with HeFH (Cuchel et al., 2014). Confirming 
variants affecting both alleles of the LDLR or other causative gene has implications for 
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specific treatment modalities for this condition. Statins and PCSK9 inhibitors both work 
by increasing the presence of LDLRs on the cell surface; the effectiveness of these 
treatments in individuals with two (bi-allelic) causal LDLR variants will depend on the 
residual function of the mutated alleles. For instance, individuals who have at least one 
LDLR allele with predicted residual function (>2% function) show up to 25% LDL-C 
reduction with the PCSK9 inhibitor evolocumab, while individuals who have two null 
LDLR variants (no LDLR functionality) show no response to this treatment (Raal et al., 
2015).  
 Two additional medications - lomitapide and mipomersen - are approved for the 
care of HoFH patients, which address the limitation of statins and PCSK9 inhibition in 
those with two mutated LDLR alleles (the most frequent cause of HoFH). These drugs 
lower LDL-C independent of LDLR function, however, have several side-effects and 
thus are generally only administered in these specific LDLR mutant HoFH cases (Gouni-
Berthold & Berthold, 2015). LDL apheresis (plasma exchange to remove LDL-C; often 
every two weeks) is another treatment often necessary for HoFH individuals with two 
mutant LDLR alleles. On the other hand, confirming “double heterozygosity” in a HoFH 
patient means that at least one wild-type LDLR allele is present; these patients are 
expected to respond well to statins and/or PCSK9 inhibition (Shirahama et al., 2018), and 
thus, this genotypic information can help avoid any premature application of the 
aforementioned (often unpleasant) treatments. 
 Importantly, therapeutic implications from genetic testing can also occur when 
LALD (bi-allelic variants in LIPA) and sitosterolemia (bi-allelic variants in ACBG5/8) 
phenocopy cases are identified. Statins are not advisable in LALD since they burden 
lysosomes with even more cholesterol than what is already presently toxic in these 
patients – possibly worsening disease (Bernstein et al., 2013). By the same virtue of 
increased LDLR presence, use of PCSK9 inhibitors are also unadvised. Treatments for 
LALD patients are limited, although there is promise in a recently approved recombinant 
LAL replacement therapy called sebelipase alfarequire (Burton et al., 2015; Hollak & 
Hovingh, 2015). For those identified with sitosterolemia, dietary restriction of foods rich 
in plant sterols (ex. vegetable oils, wheat germs, nuts, seeds, avocado, shortening, 
margarine, and chocolate) can have drastic effects on lowering LDL-C, and is the 
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mainstay of therapy (Yoo, 2016). We have experienced this in our laboratory this year: a 
fellow cardiologist sent a patient’s DNA sample to us for sequencing analysis; this was a 
18-month old infant believed to be HoFH with a LDL-C of 18 mmol/L and tendon 
xanthomata. Instead of variants in LDLR, APOB, PCSK9, or LDLRAP1, we identified 
pathogenic compound heterozygous variants in ABCG5, and this infant was re-diagnosed 
with sitosterolemia. A small change in her diet reduced her LDL-C to 9 mmol/L almost 
immediately.  
With respect to HeFH due to a single mutated allele, recent whole-exome 
sequencing data indicate that among individuals with LDL-C >5 mmol/L, the risk of 
early CHD rose from 6-fold to 22-fold when a heterozygous disease-causing FH variant 
was detected (Khera et al., 2016). While the authors suggested that more aggressive 
treatment is warranted in the latter instance, the clinical difference between a 6- or 22-
fold increased risk seems moot: both types of patients with elevated LDL-C should be 
managed aggressively.  
Among HeFH patients, the mutation status largely predicts the degree of LDL-C 
elevation: heterozygous LDLR variants generally underlie a more severe LDL-C 
phenotype, while LDL-C levels are not quite so elevated with heterozygous APOB or 
PCSK9 variants, or among individuals with a high polygenic burden (Wang et al., 2016). 
The latter groups can be more often managed with statin monotherapy alone than 
individuals with heterozygous LDLR variants, who more often would require 
combination therapy. Further, among LDLR variants, LDL-C elevation is greater amongst 
individuals with CNVs, nonsense and splicing variants (i.e. more deleterious variant 
types) than those with missense variants, again correlating with the need for more 
aggressive treatment using combinations or the more potent PCSK9 inhibitors. On the 
other hand, irrespective of the specific genetic basis, the degree of LDL-C elevation and 
the empirical response to treatment, which itself varies widely, will help guide the 
"personalized" treatment plan for the patient.  
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1.4.3 Other reasons to seek the genetic basis in patients 
suspected to have FH 
 
Mutation status information may also be important for genetic counselling. Phenotypic 
expression is highly penetrant in heterozygous carriers of FH-associated variants, 
especially in children (Sjouke et al., 2016). Although not considered to be appropriate for 
prenatal screening, because it is so eminently treatable, some families might appreciate 
knowing the discrete genetic basis for their hypercholesterolemia. A positive genetic test 
result can also have an impact on the patient's and healthcare provider's attitude; many 
patients find the information empowering and motivating, especially since much can be 
done to reduce development of hard cardiovascular clinical end points (Yuan, Wang, & 
Hegele, 2006). A genotype-based diagnosis rules out a purely environmental cause of 
high LDL-C, and although improvement of diet and exercise can reduce LDL-C levels 
(Yu-Poth et al., 1999), knowledge of an underlying genetic contribution suggests to the 
patient that these interventions alone are not likely to reverse the phenotype. In the 
Netherlands, those who received a positive test result had lower LDL-C levels compared 
to those without positive genetic testing, due to improved long-term treatment and life-
style compliance (Umans-Eckenhausen et al., 2003). 
 
 
 What genetic testing is available for FH? 
 
 
1.5.1 DNA hybridization assays 
 
DNA hybridization arrays are designed to test only for the presence of a limited number 
of specific known disease-causing variants. Typically, such arrays contain the most 
common causal variants detected within a specific geographical location or jurisdiction; 
the content is necessarily limited by the selected variants and is frozen based on the 
knowledge at the time of design and manufacture. Examples of available arrays for FH 
include: 1) the Elucigene FH20 Array (Tepnel Diagnostics, Abingdon, UK) which 
screens for the 20 most common FH-causing variants reported in the United Kingdom; 2) 
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the FH Multiplex Array (Randox Laboratories, Crumlin, UK) which screens for some of 
the 40 most common FH variants in the UK with a special attention to those within 
Ireland; and 3) the LIPOchip (Progenika Biopharma, Derio, Spain) designed for detection 
of 251 common FH variants (242 in LDLR, 3 in APOB and 6 in PCSK9).  
Advantages of DNA hybridization arrays include low cost and efficiency, but 
with caveats. The process requires very little bioinformatics processing and 
interpretation, with minimum required training for staff, and theoretically a rapid turn-
around-time for results. However, if the sample is negative for the particular set of 
variants embedded in the array, clinicians or diagnostic laboratories would require more 
comprehensive and unbiased NGS methods to obtain a genetic diagnosis, which could 
have been sought initially. Furthermore, if new FH variants are introduced into a region 
through migration, unless the variants are already on the array, they will be missed (false-
negatives); the array design would need to be periodically updated. In addition, since 
arrays cannot detect new variants, they are not useful for variant discovery. Other 
disadvantages include the lack of flexibility to cover the entire range of small-scale DNA 
variants such as indels that would be captured by Sanger sequencing or NGS approaches, 
not to mention inability to globally detect large-scale CNVs, although these could be 
included in the array design for already known CNVs, or if the sequence surrounding the 
breakpoint was known. Finally, a positive test for a single variant could be misleading in 
a compound or double heterozygote whose second variant was not represented on the 
array.  
 
1.5.2 Sanger sequencing  
 
Between about 1990 and 2015, Sanger re-sequencing of polymerase chain reaction 
(PCR)-amplified coding regions of the LDLR gene (18 exons plus intron-exon 
boundaries) and specific regions of APOB (e.g. exons 26 and 29 encoding receptor 
binding domains) and more recently the PCSK9 gene was the most commonly used 
method for diagnosis and detection of new variants. However, the method is time-
consuming and expensive on a per-nucleotide basis. Also, some regions, such as exon 1 
of both LDLR and APOB genes are relatively refractory to reliable Sanger sequencing for 
20 
 
technical reasons. Despite cost and labor-intensiveness, Sanger sequencing is still 
commonly used by diagnostic laboratories to re-sequence NGS-targeted areas that have 
low or inadequate technical coverage, to confirm NGS-detected variants, and as a 
dedicated method to screen family members of an index case for a single specific 
causative variant.  
 
1.5.3 Next-generation sequencing (NGS) platforms 
 
"Next-generation" refers to the emergence in recent years of DNA sequencing techniques 
using a variety of new, non-Sanger based chemistries (Farhan & Hegele, 2014). While 
there are numerous manufacturers in this space, including Roche/454, Life Technologies, 
Novogene and Complete Genomics, Illumina's platforms have become dominant for both 
clinical and research applications. Most NGS methods, regardless of their proprietary 
sequencing chemistry, have three main components: 1) fragmentation of source DNA 
into millions of small random pieces, which are used to prepare sequencing libraries; 2) 
amplification and enrichment, usually by immobilizing the DNA, which expedites 
hundreds of thousands of simultaneous NGS chemical reactions; and 3) detection of the 
signals from this massive series of sequencing reactions. Given the vast amount of data 
generated, it is critical to have an integrated and validated bioinformatics pipeline, which 
assembles millions of overlapping "shotgun" small fragment sequencing "reads" into a 
string of large contiguous sequence information. The sample sequence is then compared 
to a reference human genome database, generating a smaller manageable list of sequence 
variations. Using further prioritization criteria, potentially pathogenic or causative 
variants related to the phenotype of interest (i.e. FH) are pulled from this list, curated and 
evaluated, sometimes manually. 
 There are several NGS approaches to clinical diagnosis of a disorder where the 
causative gene(s) are already known, such as FH. For instance, the sample can be 
processed using whole-genome or whole-exome sequencing platforms (WGS or WES, 
respectively), which generate the entire genomic coding plus non-coding or coding-only 
DNA sequence, respectively. But since the vast majority of the generated WGS or WES 
data are not relevant for focused diagnosis of a specific condition like FH, only a tiny 
21 
 
"slice" of the generated data - a few genes - is closely interrogated to detect potentially 
clinically relevant variants. The remaining 99.9-plus percent of the generated WES or 
WGS data are masked or discarded. Conceptually, the approach of "slicing" WGS or 
WES data to find variations in a few candidate genes seems wasteful. In addition to cost 
considerations, potential ethical issues also arise because incidental findings relevant to 
many other diseases reside within WES or WGS data. Thus, another approach is to use 
NGS chemistry and throughput but within a structured targeted sequencing panel, in 
which reagents are designed only to detect variants from the outset in a limited number of 
genes known to be relevant to the disease of interest. 
 The first example of such a targeted NGS panel for lipid disorders, including FH, 
is called LipidSeq, which is an Illumina-based platform that was developed in our 
laboratory in 2013 (Johansen et al., 2014). The LipidSeq panel screens coding regions 
and intron-exon boundaries of 73 lipid metabolism-related genes, including LDLR, 
APOB, PCSK9, LDLRAP1, APOE, STAP1, LIPA, and ABCG5/8. The LipidSeq panel also 
contains reagents to detect common single nucleotide polymorphisms (SNPs) that have 
been shown in GWAS studies to be associated with subtle variations in plasma lipids 
(Kathiresan et al., 2009; Teslovich et al., 2010; Willer et al., 2013), allowing us to 
construct polygenic risk scores for plasma lipoprotein traits, including LDL-C (Wang et 
al., 2016). The advantages of a targeted NGS panel over WES or WGS for FH include: 1) 
lower cost; 2) greater bandwidth, allowing for more samples to be processed 
simultaneously; 3) greater speed of processing; 4) design that allows for simultaneous 
detection of monogenic rare large-effect variants and specific polygenic small-effect 
variants; and 5) minimizing ethical issues related to incidentally detecting disease-
causing variants in genes unrelated to lipid metabolism. Finally, it is important to 
appreciate that targeted NGS can be used in tandem with other sequencing methods. For 
instance, our laboratory confirms some variants detected on LipidSeq using Sanger 
sequencing. Also, samples from patients with definite FH by SBR or DLCN criteria that 
are LipidSeq-negative for rare variants or high polygenic scores can subsequently be 
evaluated using WES or WGS to detect new disease-causing gene loci and variants. 
 Since our laboratory’s initial report of the feasibility of targeted NGS for lipid 
disorders (Johansen et al., 2014), several diagnostic laboratories have designed 
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commercially available NGS panels (Table 1.2). In addition to complete analysis of 
LDLR coding regions, NGS panels often include the genetic screening of all coding 
regions of APOB and PCSK9. Because causative variants for FH are now being identified 
outside of the traditionally Sanger-sequenced APOB regions (exons 26 and 29) (Alves et 
al., 2014), and throughout the entire PCSK9 gene (Dron & Hegele, 2017), the increased 
capacity of targeted NGS represents an important advance over Sanger sequencing. 
Furthermore, the flexible design of an NGS-based platform allows for future relevant 
genes to be included without markedly impacting upon cost. Some providers also extend 
their panels to include, as in LipidSeq, all minor FH-associated genes, further reducing 
the chances of false-negative findings.  
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Table 1.2. Targeted NGS panels commercially available for FH genetic diagnosis. 
 
Information taken from company websites as part of  review performed March 2017; not 
an exhaustive list.  
 
 
  
 
Service Primary FH Genes Additional Genes 
Turn Around 
Time 
FH Reflex Panel 
Mayo Clinic 
Rochester, MN, USA 
LDLR,  
APOB (p.Arg3527) 
None 2 weeks 
FH NGS Panel 
DDC Clinic 
Middlefield, OH, USA 
LDLR, APOB, PCSK9 LDLRAP1 4-6 weeks 
FH Sequencing Panel 
Prevention Genetics 
Marshfield, WI, USA 
LDLR, APOB, PCSK9 LDLRAP1 4 weeks 
FH Panel 
GeneDX 
Gaithersburg, MD, USA 
LDLR, APOB, PCSK9 LDLRAP1 4 weeks 
FH Panel 
Invitae 
San Francisco, CA, USA 
LDLR, APOB, PCSK9 LDLRAP1 1-3 weeks 
FHNext Panel 
Ambry Genetics 
Aliso Viejo, CA, USA 
LDLR, APOB, PCSK9 LDLRAP1, SLCO1B1(SNP c.521T>C) 2-3 weeks 
GeneSeq: CAD/FH 
Profile 
Integrated Genetics 
Westborough, MA, USA 
LDLR, APOB (556bp of 
exon 26), PCSK9 
ABCA1, APOA2, APOC3, PON2 
SHOC2 (exon 2), AKAP9 (exon 18) 
6-8 weeks 
FH Panel 
ApolloGen 
Irvine, CA, USA 
LDLR, APOB, PCSK9 
ABCA, ABCG1/5/8, APOA/1, APOE 
APOC2/3/4, CETP, LCAT, LIPA, LIPC, 
LPA, LPL, MYLIP, NPC1 
4 weeks 
SEQPRO LIPO IS 
Progenika Biopharma 
San Marcos, TX, USA 
Derio, Spain 
LDLR, APOB, PCSK9 LDLRAP1, APOE, STAP1 4-6 weeks 
Hypercholesterolemia 
Panel 
Sophia Genetics 
Saint-Sulpice, 
Switzerland 
LDLR, APOB, PCSK9 LDLRAP1, APOE 2-3 weeks 
FH/Comprehensive 
Panel 
HealthInCode 
A Coruña, Spain 
LDLR, APOB, PCSK9 
LDLRAP1, APOE, SLCO1B1 
Comprehensive option includes: 
ABCG5/8, LIPA, LPA, NPC1L1, 
ABCB1, AMPD1, CH25H, COQ2, 
CPT2, CYP2D6, CYP3A/5, 
PPARA, PYGM, RYR1, SLC22A8 
1-3 weeks 
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1.5.4 Determining pathogenicity of identified variants 
 
When any analytic method detects a variant in a FH-related gene, how do we know that 
the variant is clinically relevant, i.e. disease-causing? This general problem arises from 
the exponentially growing clinical and research applications of NGS, which can identify 
dozens or hundreds of rare variants (i.e. allele frequency of <1% in control population 
databases) per sample analyzed (dependent on the number of genes and regions 
assessed). The clinical and human genetics community is responding to this challenge by 
producing guidelines and position statements about potential pathogenicity (Green et al., 
2016). An important element is the creation and maintenance of reliable databases of 
clinically relevant variants, of which ClinVar at the National Center for Biotechnology 
Information (NCBI) is becoming widely accepted (Landrum et al., 2014).  
Imputing a causal role for any particular variant in FH is not an established 
science; it is an evolving field. When a rare DNA variant is detected in a sample from a 
patient with suspected FH, its "first stop" would be a comparison against entries in 
publicly available databases, to determine whether it has been previously reported and to 
gauge any additional evidence which may support or refute causality.  
The "gold standard" or most undisputable form of evidence supporting a variant's 
pathogenicity is functional evidence demonstrating a biochemical effect of the variant on 
LDL-C homeostasis, often in vitro. However, at most ~15% of all reported LDLR 
variants have been studied functionally (Bourbon et al., 2017). A general issue in human 
genetics is the need to develop technologies that will scale up functional analyses of new 
variants in real time. At present, functional analysis is not practical in a clinical 
diagnostic setting. The next highest level of certainty for functional relevance involves 
major deleterious variants in LDLR, such as nonsense and frameshift variants introducing 
a premature stop codon, and large-scale deletions. These are generally considered to have 
a deleterious effect on LDLR activity and functional studies are often not required. 
Classification of CNVs or nonsense variants as "pathogenic" has traditionally been 
warranted without additional evidence.  
The majority of variants reported as "causative" for FH do not belong to the above 
categories; thus a series of further analyses could help clarify their classification. These 
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include assessing variant frequency in control population databases, providing evidence 
of co-segregation of variant and affected status in families, and use of various in silico 
tools to predict impact on protein function. However, such interpretation efforts for any 
particular variant are often rudimentary and differ from one diagnostic laboratory to the 
next, leading to inaccuracies and inconsistencies in pathogenicity classification – an issue 
documented within the clinical genetics field (Harrison et al., 2017). In 2015, the 
American College of Medical Genetics and Association of Molecular Pathologists 
(ACMG/AMP) addressed this by publishing a set of consensus guidelines for 
standardized variant interpretation in Mendelian disorders (Richards et al., 2015). Within 
the ACMG/AMP framework, an algorithm-based scoring method classifies variants 
within a 5-tier system as either "pathogenic", "likely pathogenic", "variant of unknown 
significance (VUS)", "likely benign", or "benign" based on 28 different evidence types 
with varying weightings. This formal structure facilitates a more critical and consistent 
assessment of evidence for or against pathogenicity (Richards et al., 2015). Thus, by 
today’s standards it is becoming more commonly suggested that only those variants 
classified as "pathogenic" or "likely pathogenic" by these standardized guidelines be used 
to confirm a clinical diagnosis of FH. 
  
1.5.5 CNV analysis in the diagnosis of FH 
 
Rare CNVs causing a loss of function in LDLR have long been recognized as a 
significant class of FH variants. Revisiting the pioneering work of Nobel Laureates 
Joseph Goldstein and Michael Brown shows that LDLR structural rearrangements - that 
we would now term CNVs - were a prevalent variant-type in some of their earliest 
characterized FH patients and families (Hobbs, Brown, & Goldstein, 1992), due to the 
use of Southern blotting as the main technology to detect DNA variation before 1988. 
Southern blotting was ideally suited to detect DNA fragment sizes ranging between 0.5 
and ~18 kilobases, so aberrant patterns of LDLR gene bands in this size range due to a 
CNV in an affected patient were readily detectable. Some early reported LDLR CNVs 
were founder-effect variants, contributing to a high proportion of FH in distinct 
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populations, such as the 15-kilobase deletion spanning the promoter and exon 1, seen in 
60% of French-Canadians with FH (Hobbs et al., 1987), or the 9.5-kilobase deletion 
spanning exons 16-18, seen in 30-40% of Finns with FH (Aalto-Setala et al., 1987; 1992).  
PCR-based methods coupled with automated Sanger sequencing became the state-
of-the art methodology to identify DNA variation around 1990. These robust tools were 
optimized to detect small-scale changes. Over the following 15 years, almost all reported 
LDLR variants in FH were thus rare single nucleotide variants - underlying missense, 
nonsense, splicing - and small indel variants resolvable by Sanger sequencing. When a 
large-scale CNV was present, it was not observable, analogous to ascertaining a canyon 
using a magnifying glass that was optimized to detect flaws on stone's surface. If an exon 
or exons of a mutated LDLR allele were missing, only the corresponding region on the 
normal allele remained; this would be read as normal sequence qualitatively, but there 
was no way to know that the read-out was based on a hemizygous genomic substrate 
rather than two normal diploid alleles.   
This limitation was addressed around 2003, with use of a technology designed to 
determine DNA-dosage alterations by hybridizing specialized DNA probes directed 
against specific regions, namely exons of the LDLR. This method, multiplex ligation-
dependent probe amplification (MLPA), is well-suited for LDLR analysis due to its 
dedicated exon-by-exon level resolution, relevant to the range of CNV events known to 
disrupt the LDLR gene in FH (see Figure 1.3 above). MLPA, which has been proven 
ultra-reliable for over a decade, is considered the gold standard for CNV detection in 
LDLR. Because ~10% of patients with FH in various cohorts were found to have CNVs 
detectable by MLPA, it was necessary to set up two different methods - Sanger 
sequencing plus MLPA - to maximize the variant detection rate 
However, because MLPA requires additional infrastructure, reagents, expertise, 
and analysis time, it has always been a goal to find a unified method that could both 
detect small-scale sequence variants - i.e. single base pair variants and small indels - and 
large-scale CNVs from a single chemical reaction and analysis platform, for instance, 
from NGS results.  
 
 
27 
 
1.5.6 Analysis of polygenic elevated LDL cholesterol 
 
The presence of multiple common LDL-C raising alleles is another possible cause of 
hypercholesterolemia. Because 20-40% of individuals with phenotypic HeFH have no 
identifiable monogenic variants, incorporating polygenic analysis into the routine testing 
strategy has significant potential to assist in genetically defining cases. Polygenic testing 
in FH is done with the construction of a genetic risk score (GRS, or sometimes referred to 
as a polygenic trait score; PTS). Fundamentally, a GRS summarizes information across 
multiple SNPs into a single, predictive score. The simplest iteration sums the number of 
risk-alleles found at each selected trait-altering locus, either 0, 1, or 2, for a non-risk 
homozygous state, a risk heterozygous state, or a risk homozygous state, respectively. In 
this way, its calculation assumes an identical directional effect conferred by each risk 
allele included in the score. For complex traits such as LDL-C, however, effect sizes vary 
across significantly associated GWAS SNP loci (Teslovich et al., 2010; Willer et al., 
2013), thus assigning each loci these weighted values is thought to improve the overall 
score’s predictive ability.  
At present, there have been multiple reports of GRSs for LDL-C in cohorts with 
suspected FH (Futema et al., 2014, 2015; Sjouke et al., 2016; Talmud et al., 2013; Wang 
et al., 2016). However, there is no consensus regarding the optimal set of SNP markers to 
include in such a score; different reports have used different SNPs, so the results are not 
directly comparable. The individual SNPs used in particular reported GRSs are shown in 
Table 1.3.  
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Table 1.3. SNPs used in reported genetic risk scores for hypercholesterolemia. 
SNP Locus 
Risk 
Allele 
GLGC Effect Size 
(mmol/L) 
Talmud 
et al. 
(2013) 
Futema 
et al. 
(2016) 
Wang 
et al. 
(2016) 
Sjouke 
et al. 
(2016) 2008 2010 2013 
rs6511720 LDLR G 0.26 0.18 0.22 x x x x 
rs629301 SORT1 T - 0.15 0.17 x x  x 
rs1367117 APOB A - 0.10 0.12 x x  x 
rs10401969 NCAN/CILP2 T 0.05 0.12 0.12   x  
rs4299376 ABCG8 G - 0.07 0.08 x   x 
rs3846663/rs12916 HMGCR T/C 0.07 0.06 0.07   x  
rs1800562 HFE G - 0.06 0.06 x   x 
rs2479409 PCSK9 G - 0.05 0.06 x x  x 
rs11220462 ST3GAL4 A - 0.05 0.06 x   x 
rs1501908/rs6882076 TIMD4 C/C 0.07 0.04 0.05   x  
rs1564348 LPA T - 0.01 0.05 x   x 
rs2650000/rs1169288 HNF1A A/C 0.07 0.04 0.04   x  
rs3757354 MYLIP C - 0.04 0.04 x   x 
rs8017377/rs2332328 NYNRIN T/T - 0.03 0.04 x   x 
rs12740374 SORT1 G 0.23 - -   x  
rs515135 APOB C 0.16 - -   x  
rs6544713 ABCG8 T 0.15 - -   x  
rs11206510 PCSK9 T 0.09 - -   x  
rs6102059 MAFB C 0.06 - -   x  
rs429358 
rs7412 
*APOE 
ε2ε2 
ε2ε3 
ε2ε4 
ε3ε3 
ε3ε4 
ε4ε4 
-0.90 
-0.40 
-0.20 
0 
0.10 
0.20 
  x x  x 
 
SNPs and effect sizes have been reported by the Global Lipids Genetics Consortium 
(GLGC), in three successive reports (Kathiresan et al., 2009; Teslovich et al., 2010; 
Willer et al., 2013) meta-analyzing GWAS for lipid-associated traits. SNPs denoted by “ / 
” are proxies (Teslovich et al., 2010). *APOE SNPs and effect sizes were reported in 
(Bennet et al., 2007), and were not identified in the GLGC reports. 
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 Synopsis 
 
 
FH is extremely prevalent, yet severely underdiagnosed – despite being eminently 
treatable. Recently, FH has progressed toward the forefront of precision medicine as 
patients worldwide are increasingly offered genetic testing as a central part of diagnosis. 
Advantages of providing a genetic diagnosis for FH are manifold.  They include: 1) 
achieving certainty in the context of incomplete clinical criteria, such as family history or 
typical physical findings; 2) motivating cascade screening and thus early diagnosis and 
preventative treatment in affected family members; 3) initiating genotype-directed 
treatment strategies; 4) improvement of treatment compliance; and 5) supporting 
insurance coverage of certain medications.   
 Genetic testing in FH is recommended by the Canadian Cardiovascular Society 
(Brunham et al., 2018), the US Centers for Disease Control Office of Public Health 
Genomics (Gidding et al., 2015), the United Kingdom National Institutes for Clinical 
Excellence (NICE), both the European and International Atherosclerosis Societies, and an 
international expert panel convened by the FH Foundation and American College of 
Cardiology (Sturm et al., 2018). The American College of Medical Genetics and 
Genomics also includes LDLR, APOB, and PCSK9 among the list of 56 “medically 
actionable” genes for which sequence analysis can lead to direction of treatment (Green 
et al., 2013). Given both its prominence and importance, my thesis focuses on improving 
the strategies currently used to provide a genetic diagnosis of FH. 
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Chapter 2 – Use of next-generation sequencing to detect 
LDLR gene copy number variation in the genetic diagnosis 
of FH 
 
2  
Chapter 2 was adapted from the independent study “Use of next-generation sequencing to 
detect LDLR gene copy number variation in familial hypercholesterolemia”, published in 
the Journal of Lipid Research in 2017 (Iacocca et al., 2017; PMID: 28874442).  
 
 
 Introduction 
 
Successful genetic diagnosis depends on the ability of the designated method to 
assess both locus and allele heterogeneity associated with FH. The cost-effectiveness of 
such methods may limit their widespread implementation and routine use. Currently, the 
procedure employed in “best practice” diagnostic laboratories is 1) the use of targeted 
next-generation sequencing (NGS) panels for the detection of small-scale DNA variants - 
i.e. single base pair variants and small indels – which commonly are designed to assess 
all coding and intronic splice-site regions in LDLR, APOB, and PCSK9 (and less 
commonly also in LDLRAP1, APOE, STAP1, LIPA, ABCG5/8), followed by 2) the use of 
multiplex-ligation dependent probe amplification (MLPA), for the detection of large-
scale CNVs in LDLR. The latter bench method has proven to be essential in the routine 
screening strategy for FH as ~10% of defined FH cases have been attributed to CNVs in 
LDLR (Bourbon et al., 2017); screening for them avoids false-negative diagnoses. 
However, while MLPA has been considered the “gold standard” for CNV detection in 
LDLR for the last decade or more, not all diagnostic laboratories have the infrastructure, 
resources, time, or interest to establish this parallel system despite its importance.  
 With use of NGS methods, comes the opportunity to detect CNVs. To be certain 
about single nucleotide variation from a genomic template, the library of derived short 
overlapping NGS fragments must redundantly encompass any particular nucleotide 
multiple times, particularly to ensure that heterozygous variation can be unambiguously 
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detected. A useful metaphor is the flipped coin - if heads are seen with each of only 5 
flips, the presence of a side with "tails" cannot be ruled out with as much certainty as 
when "heads" appear consistently after 30 flips. This attribute of NGS data is referred to 
as "depth of coverage" (DOC); the standard DOC for NGS research applications is 30-
fold, i.e. each base is read independently from a minimum 30 different synthesized 
fragments. For clinical applications, the required DOC can be much higher, often ~300-
fold. 
The large number of synthesized derived overlapping fragments required to 
maximize DOC in NGS offers an opportunity to determine not just qualitative but also 
quantitative aspects of the genomic region being interrogated. In general, the number of 
synthesized fragments follows stoichiometrically from the quantity of starting material. If 
there is half as much genomic template (i.e. only one copy instead of two), the resulting 
DOC reflected in the number of synthesized fragments will be reduced by half. If this 
involves a contiguous DNA region, then the DOC across the region will be reduced by 
50% compared to normal neighboring regions. Similarly, for a duplicated genomic 
region, an increased number of DNA fragments are available to be read. This additional 
information from NGS data may be quantified using specific bioinformatic tools, with 
potential for CNVs to be detected.   
Here, we determined the potential of replacing MLPA with bioinformatic analysis 
applied to NGS data for the detection of LDLR CNVs in FH patients. In analysis of 388 
FH patient samples, we demonstrated 100% concordance in LDLR CNV detection 
between these two methods: 38 reported CNVs identified by MLPA were also 
successfully detected by our NGS method, while 350 samples negative for CNVs by 
MLPA were also negative by NGS. This result suggests that MLPA can be removed from 
the routine diagnostic screening for FH, significantly reducing associated costs, 
resources, and analysis time, while promoting more widespread assessment of this 
important class of variation across diagnostic laboratories. 
 
 
 
41 
 
 Materials and Methods 
 
 
2.2.1 Study subjects 
 
We studied 388 Canadian individuals aged ≥ 18 years who were referred to the London 
Health Sciences Centre, University Hospital (London, ON) for treatment of severe 
hypercholesterolemia. Diagnosis of at least “possible FH” was made using the Dutch 
Lipid Clinic Network (DLCN) criteria; all patients had untreated LDL-C ≥ 5 mmol/L, 
plus family history of hypercholesterolemia, plus some with either personal or family 
history of premature CHD. Our protocol was approved by the Western University 
Research Ethics Board (No. 07920E) and all participants provided informed consent for 
genetic analyses.  
 
2.2.2 Targeted next-generation sequencing  
 
Genomic DNA was isolated from whole blood using the Puregene DNA Blood Kit 
(Gentra Systems, Qiagen, Mississauga, ON, Canada), and was subject to targeted NGS 
using our LipidSeq panel (Johansen et al., 2014). With LipidSeq, each sample is 
sequenced for 73 key genes in lipid metabolism, including all coding regions, ~150 base 
pairs (bp) at intron-exon boundaries, and ~250 bp of the 5’ untranslated region (UTR) of 
all FH-associated genes LDLR, APOB, PCSK9, LDLRAP1, APOE, STAP1, LIPA, 
ABCG5, and ABCG8. Library preparation was performed using the Nextera Rapid 
Capture Custom Enrichment kit (Illumina, San Diego, CA), and enriched samples were 
sequenced on a MiSeq personal sequencer platform (Illumina) using 2 x 150 bp paired-
end chemistry and in accordance with manufacturer instructions. MiSeq-generated 
.FASTQ files were downloaded and processed individually using a custom automated 
workflow in CLC Genomics Workbench version 8.51 (CLC Bio, Aarhus, Denmark) for 
sequence alignment (mapped to human genome build GRCh37/hg19), variant calling 
(generation of .VCF files), and target region coverage statistics (generation of .BAM 
files). Our LipidSeq method has an average depth of coverage of 300-fold for each base.  
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2.2.3 CNV detection by MLPA 
 
The MLPA Salsa P062-D2 kit (MRC Holland, Amsterdam, Netherlands) was used for the 
detection of large-scale whole-exon deletion and duplication events in LDLR. The P062-
D2 kit contains 20 probes for LDLR (one for each of the promoter and all 18 exons, with 
the exception of two for exon 15), plus one flanking probe for upstream of LDLR and 12 
reference probes for gene loci on alternative autosomal chromosomes. The probe-mix 
also contains 9 control fragments that generate short products to indicate that the DNA 
quantity and ligation reaction are sufficient for proper analysis. The principles and stages 
of probe hybridization are as previously described (Schouten et al., 2002), and protocol 
followed the manufacturer’s guide version MDP-005 (www.mrc-holland.com). PCR 
amplification was carried out in a Veriti thermocycler (Applied Biosystems, Foster City, 
CA) and products were subsequently analyzed using a 3730 Automated DNA Sequencer 
(Applied Biosystems). MLPA fragment analysis was performed using Coffalyser 
software version 140721.1958 (MRC Holland; www.coffalyser.net), where relative 
amounts of probe-amplified products are compared with normal controls (samples within 
the same run) to determine the copy number state for each target region. We used one 
normal control sample per 7 study samples. Ratio values < 0.75 indicating copy number 
loss and > 1.33 indicating copy number gain were flagged. Two-sample t-tests were used 
for all statistical comparisons against the profiles of normal controls (P < 0.05).  
 
2.2.4 CNV detection by NGS data 
 
The bioinformatics tool CNV Caller, an application within the variant annotation 
software VarSeq v1.4.3 (Golden Helix, Bozeman, MT), was used for analysis of our 
existing LipidSeq data set for CNV detection. VarSeq CNV Caller requires .VCF and 
.BAM files (generated by NGS; see above) as inputs for each sample, plus a .BED file 
which defines the target region chromosomal and probe start/stop coordinates for the 
specific NGS panel used. The VarSeq algorithm uses normalized depth of coverage 
(DOC) analysis as its principal method, whereby an increase in sample DOC across a 
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target region, when compared to reference controls, suggests a gain in genomic material; 
and a decrease in sample DOC suggests a loss.  
To first normalize the raw coverage data, the VarSeq algorithm uses a set of 
matched reference controls. We provided the algorithm a population of > 100 normal 
controls, from which it selects 30 with the lowest percent difference in coverage data 
compared to the sample of interest; samples are flagged if the average percent difference 
is > 20%. Matched reference controls are further used to correct for GC-content bias and 
regions that are relatively unamenable to mapping. A ratio and z-score metric are then 
computed for each target region. The ratio is calculated as the sample coverage divided 
by the mean reference sample coverage. The z-score measures the number of standard 
deviations that a sample’s coverage is from the mean reference sample coverage. A 
Bayesian frame network model then assigns CNV state based on the probability that for 
each target region these two metrics represent either a: 1) diploid (normal) state; 2) 
heterozygous deletion; 3) homozygous deletion; or 4) duplication event. Further, the 
algorithm also exploits SNP heterozygosity information across a target region as an 
additional supporting metric for assigning CNV state. Denoted as variant allele 
frequencies (VAF), a VAF of any non 0 or 1 value provides further evidence against 
deletions, whereas a VAF such as 1/3 or 2/3 provides further evidence for duplications. 
Finally, segmentation analysis merges multiple affected target regions to characterize 
contiguous CNV events; the minimum limit of CNV detection is the smallest whole-exon 
(lower limit ~300 base pairs) while the maximum limit is the entire LDLR gene 
(approximately 18 kilobases). 
 
2.2.5 CNV filtration 
 
Following CNV analysis, CNVs were filtered based on mutually inclusive ratio and z-
score thresholds. A ratio threshold value of ≤ 0.7 and z-score of ≤ -5.0 were used to 
identify probable heterozygous deletions, whereas a ratio value of ≥ 1.30 and z-score of ≥ 
5.0 were used for duplications. For further validation, evidence from target region VAF’s 
were also manually evaluated as explained above.  
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2.2.6 Statistical analyses 
 
Analyses of demographic features were performed in SAS version 9.1 (SAS Institute, 
Cary NC). Quantitative traits were compared using unpaired t-tests, while discrete traits 
were compared using chi-square analysis, typically 2 X 2 contingency analyses. The 
nominal level of statistical significance was set at P < 0.05. 
 
 
 Results 
 
 
2.3.1 Study sample demographics 
 
Baseline clinical and biochemical features of the individuals studied here are shown 
below in Table 2.1. 
 
Table 2.1. Canadian FH cohort patient demographics. 
 Overall 
(N=388) 
Women 
(N=212) 
Men 
(N=176) 
Age, years 50.715.2 52.116.3 48.913.6 
Body mass index, kg/m2 27.85.9 27.36.1 28.65.5 
Total cholesterol, mmol/L 8.941.91 9.131.94 8.661.83 
LDL cholesterol, mmol/L 6.791.79 6.931.80 6.601.76 
HDL cholesterol, mmol/L 1.350.38 1.430.39 1.220.35 
Triglyceride, mmol/L 1.790.88 1.770.98 1.810.73 
Personal history of CVD, *% 17.9 12.9 25.0 
Family history of CVD, *% 40.0 44.7 50.0 
Definite or probable FH (DLCN score), *% 65.5 67.1 63.3 
 
Values are represented as mean±standard deviation. CVD indicates cardiovascular disease 
(onset <55 years in men, <60 years in women). DLCN; Dutch Lipid Clinic Network. 
*Based on complete data from 145 individuals. 
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2.3.2 CNVs detected by MLPA 
 
Thirty-eight (9.8%) of 388 FH patients were positive for whole-exon CNVs in LDLR 
detected by MLPA (Table 2.2). The majority (35 of 38; 92.1%) of these patients had 
heterozygous deletions, of which 13 spanned multiple exons. There were 3 detected 
duplications. The most common CNV involved a heterozygous deletion of the promoter 
and exon 1, found in 22 of 38 (57.9%) CNV-positive patients. Exon 6 was affected in 6 
of 38 (15.8%) patients. Of the 18 exons in LDLR, only exons 8, 9 and 10 were unaffected 
by CNV events among the study sample. All control samples had normal MLPA profiles. 
Sample outputs from MLPA for two different types of CNVs are shown in Figures 2.1A 
and 2.2A. 
 
2.3.3 CNVs detected by NGS data 
 
Thirty-eight (9.8%) of 388 FH patients were positive for CNVs in LDLR detected by 
NGS. These CNVs and their associated states were in 100% concordance with those 
detected by MLPA (Table 2.2). Furthermore, the 350 samples negative for CNVs by 
MLPA were also negative by NGS. Using MLPA as the “gold standard" there were no 
false positives and no false negatives using our bioinformatics procedure applied to NGS 
data, which translates to a diagnostic test specificity and sensitivity of 100% each (Table 
2.3). Sample outputs from VarSeq CNV Caller for two different types of CNVs 
corresponding to MLPA tracings referred to above are shown in Figures 2.1B and 2.2B. 
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Table 2.2. LDLR gene whole-exon CNVs identified in 388 patients with FH. 
             MLPA NGS Data 
Sample 
Number 
Type Region Detection Ratio Z-score 
1 Het. Deletion Promoter-Exon 1 Yes 0.62 -6.1 
2 Het. Deletion Promoter-Exon 1 Yes 0.43 -9.8 
3 Het. Deletion Promoter-Exon 1 Yes 0.58 -5.6 
4 Het. Deletion Promoter-Exon 1 Yes 0.51 -6.2 
5 Het. Deletion Promoter-Exon 1 Yes 0.50 -8.2 
6 Het. Deletion Promoter-Exon 1 Yes 0.53 -7.9 
7 Het. Deletion Promoter-Exon 1 Yes 0.52 -8.7 
8 Het. Deletion Promoter-Exon 1 Yes 0.56 -8.7 
9 Het. Deletion Promoter-Exon 1 Yes 0.51 -8.6 
10 Het. Deletion Promoter-Exon 1 Yes 0.52 -7.9 
11 Het. Deletion Promoter-Exon 1 Yes 0.51 -7.5 
12 Het. Deletion Promoter-Exon 1 Yes 0.59 -6.6 
13 Het. Deletion Promoter-Exon 1 Yes 0.55 -5.4 
14 Het. Deletion Promoter-Exon 1 Yes 0.51 -6.2 
15 Het. Deletion Promoter-Exon 1 Yes 0.59 -6.0 
16 Het. Deletion Promoter-Exon 1 Yes 0.51 -8.0 
17 Het. Deletion Promoter-Exon 1 Yes 0.59 -6.6 
18 Het. Deletion Promoter-Exon 1 Yes 0.46 -8.7 
19 Het. Deletion Promoter-Exon 1 Yes 0.51 -8.1 
20 Het. Deletion Promoter-Exon 1 Yes 0.57 -6.2 
21 Het. Deletion Promoter-Exon 1 Yes 0.51 -9.8 
22 Het. Deletion Promoter-Exon 1 Yes 0.57 -6.8 
23 Het. Deletion Promoter-Exon 2 Yes 0.57 -5.6 
24 Het. Deletion Promoter-Exon 2 Yes 0.50 -9.5 
25 Het. Deletion Promoter-Exon 6 Yes 0.54 -7.4 
26 Het. Deletion Exons 2-3 Yes 0.56 -6.7 
27 Het. Deletion Exons 2-6 Yes 0.54 -9.7 
28 Duplication Exons 2-6 Yes 1.38 11.8 
29 Het. Deletion Exons 3-6 Yes 0.53 -9.7 
30 Het. Deletion Exons 5-6 Yes 0.54 -14.7 
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31 Duplication Exon 7 Yes 1.47 7.3 
32 Duplication Exons 11-12 Yes 1.86 12.7 
33 Het. Deletion Exons 11-12 Yes 0.54 -7.8 
34 Het. Deletion Exons 13-14 Yes 0.52 -15.9 
35 Het. Deletion Exons 13-15 Yes 0.65 -8.7 
36 Het. Deletion Exons 16-18 Yes 0.53 -9.9 
37 Het. Deletion Exons 17-18 Yes 0.53 -9.3 
38 Het. Deletion Exons 17-18 Yes 0.55 -10.1 
 
For multi-exon copy number variants the reported ratio and z-score values are averaged 
across each affected region. Het., heterozygous. 
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Ratio: 1.0 
Ratio: 0.5 
Z-score threshold: -5.0 
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Figure 2.1. Two methods of detection of a CNV deletion event in the LDLR gene in a 
patient with FH. A) MLPA method output: heterozygous deletion in LDLR exons 2 – 6. 
Exon numbers are shown by “LDLR-N” (where N is the number of the exon, the first 
“LDLR-1” indicates the promoter, and “SMARCA4-35” is upstream of the promoter), 
and “*Reference” indicate reference probes bound to alternative chromosomes. For each 
probe target region, two separate plots are generated: 1) the normalized reference sample 
set is represented by 1-standard deviation box plots, where “X” indicates the mean and 
the horizontal line the median probe-signal intensity; and 2) the normalized patient 
sample probe-signal ratio is overlay as a dot, and is surrounded by error bars depicting 
the 95% confidence interval. The upper arbitrary border (blue line) and lower arbitrary 
border (red line) are placed +/- 0.3 from the reference sample mean of each probe. B) 
VarSeq CNV Caller method output: heterozygous deletion in LDLR exons 2 – 6. 
Different regions of the output are as follows: i) normalized ratio metric computed for 
each LipidSeq target region in LDLR; depth of sequence coverage comparative to 
reference controls where ~1.0 indicates diploid (normal) copy number state and ~0.50 
indicates a heterozygous deletion event; ii) normalized z-score metric; number of 
standard deviations the depth of coverage is from the reference control mean coverage, 
where ≤ -5.0 is the threshold set to indicate a deletion event;. iii) CNV state, determined 
by ratio and z-score metrics together with supporting evidence from variant allele 
frequencies (not shown). Segmentation analysis has merged multiple affected target 
regions to call a contiguous heterozygous deletion event; iv) exon map of LDLR gene; 
and v) LipidSeq probe target regions. 
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Ratio: 1.5 
Z-score threshold: 5.0 
Ratio: 1.0 
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Figure 2.2. Two methods of detection of a CNV duplication event in the LDLR gene in a 
patient with FH. See legend to Figure 2.1 for overall structure of the panels. A) MLPA 
method output: duplication in LDLR exon 7. B) VarSeq CNV Caller method output: 
duplication in LDLR exon 7. Section i) normalized ratio metric computed for each 
LipidSeq target region in LDLR; depth of sequence coverage comparative to reference 
controls where ~1.0 indicates diploid (normal) copy number state and ~1.5 indicates a 
duplication event; ii) normalized z-score metric; number of standard deviations the depth 
of coverage is from the reference control mean coverage, where ≥ 5.0 is the threshold set 
to indicate a duplication event; other sections as in Figure 2.1.  
 
 
 
Table 2.3. 2 X 2 contingency analysis of CNVs called by MLPA and NGS methods. 
 
 
  MLPA result 
  CNV state Diploid 
NGS data 
result 
Positive 
True Positives 
38 
False Positives 
0 
Negative 
False Negatives 
0 
True Negatives 
350 
  
Sensitivity: 100% Specificity: 100% 
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 Discussion 
 
The ability to detect the full spectrum of DNA variation in LDLR is critical in obtaining a 
genetic diagnosis for FH, especially since up to 10% or more of such variants are large-
scale CNVs rather than small-scale variants (Bourbon et al., 2017). The current procedure 
for diagnostic laboratories often includes targeted NGS followed by MLPA. Our findings 
suggest that the information about potential CNVs also resides within NGS data, and that 
MLPA is dispensable, particularly for the LDLR gene. NGS with appropriate 
bioinformatics has the potential to identify both small and large-scale variant detection in 
a single platform and single analytic procedure.  
 Specifically, in our analysis of 388 samples referred for FH diagnosis, 38 reported 
CNVs detected by MLPA were also successfully detected by NGS; no sample that was 
positive for a CNV by MLPA was missed by our bioinformatic approach. Importantly, 
with a specificity and sensitivity of 100%, there were no false-positive or false-negative 
calls derived from NGS data compared with MLPA. Furthermore, this targeted NGS 
method identified a wide range of CNV events, including those affecting almost all 18 
exons, both single and multi-exon events, and both deletions and duplications (see Table 
2.2).  
 The prevalence of whole-exon CNVs (9.8%) in FH patients is similar in our 
cohort compared to those previously studied (Goldmann et al., 2010; Taylor et al., 2009). 
The LDLR locus is known to have an especially high frequency of Alu repeat elements, 
making it susceptible to CNV mutagenesis (Goldmann et al., 2010; Hobbs et al., 1985). 
The pattern of CNV events detected across LDLR largely correlates with the distribution 
of these Alu repeats; sequence analysis in LDLR has revealed that the large majority of 
known CNV-breakpoints are found within introns 1-8 and 12-18 / 3’UTR, which is where 
Alu elements are most concentrated (Amsellem et al., 2002). This feature might explain 
why exons 8, 9, and 10 were unaffected by CNVs in our cohort. The high frequency of 
promoter-exon 1 heterozygous deletions can be attributed to the presence of French 
Canadians in our study sample. This ~15 kilobase deletion is a well-known founder-
effect variant first discovered in 1987 to be present in ~60% of French Canadians with 
FH; presumably originating among the 8000 ancestors of the present-day French 
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Canadians who have traditionally had little cross-breeding with other ethnic groups 
(Hobbs et al., 1987). Because of the high prevalence of this specific variant, CNV 
analysis has long been an important component of FH screening in Canada.  
 For the last decade or more, MLPA has been regarded as the "gold standard" for 
CNV detection in LDLR. Prediction of CNVs from NGS data has been investigated 
previously; however, it remains a relatively new and challenging field. Commonly used 
CNV prediction programs include CoNIFER (Jiménez-Cruz et al., 2002), ExomeDepth 
(Plagnol et al., 2012), ExomeCopy (Love et al., 2011), XHMM (Fromer et al., 2012), and 
CNV-seq (Xie & Tammi, 2009), however many of these designated methods have shown 
high rates of false-positive CNVs, which poses a major limitation upon potential clinical 
use. Moreover, many of the literature reported CNV prediction programs have been 
designed and optimized for whole-genome or whole-exome NGS analysis, which is 
inherently different from targeted NGS analysis, as the latter focuses on only a few target 
genes, with known reference copy number counts, and provides a higher average 
sequence coverage per base, which in turn allows for depth of coverage (DOC) methods 
to be a suitable approach. The higher DOC for each particular LDLR base using targeted 
NGS versus whole-genome or whole-exome NGS potentially increases the sensitivity to 
detect CNVs. Finally, our study took advantage of our unique large cohort of known 
LDLR MLPA positive and negative samples as reference standards to evaluate the 
applicability of this bioinformatics approach to CNV detection in the clinical diagnostic 
context for FH.  
 Essential to the performance of DOC analysis is use of appropriate matched 
reference controls for cross-sample normalization and comparison (i.e. controls 
sequenced with the exact enrichment chemistry and NGS panel version design as the 
sample-of-interest) and quality-control thresholds set for ratio and z-score metric outputs. 
Although proven robust in detection, our methodology has some limitations in further 
defining CNVs. In the event of a called “duplication”, the VarSeq CNV Caller output 
does not specify the exact degree of amplification. By design, this feature is a result of 
the difficulty in accurately differentiating DOC metrics as copy numbers incrementally 
increase. Another limitation is the inability to determine whole-exon CNV breakpoints as 
these reside in the intronic regions which are unsequenced on our LipidSeq panel. 
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Importantly however, although such information may be useful for research purposes, it 
does not affect the documentation of a CNV for the purpose of diagnosis.  
   
 
 
 
 Conclusion 
 
In conclusion, we report 100% concordance for the detection of whole-exon CNVs in 
LDLR between a bioinformatics approach applied to existing NGS data and the “gold 
standard” reference method of MLPA. This result suggests that the latter independent 
bench method can be removed from the routine genetic diagnostic workup for FH, 
improving costs, resources, and analysis time and thus encouraging an even more 
commonplace assessment of this important class of variation across diagnostic 
laboratories in the future.  
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Chapter 3 – Novel copy number variation screening in 
secondary FH-associated genes 
 
3  
 
Chapter 3 was adapted from the independent study “Whole-gene duplication of PCSK9 as 
a novel genetic mechanism for severe hypercholesterolemia”, published in the Canadian 
Journal of Cardiology in 2018 (Iacocca et al., 2018; PMID: 30269829).  
 
 
 Introduction 
 
FH is heterogeneous at the genetic level; although most cases result from inactivating 
variants in the LDLR gene, several other genes have also been implicated, including 
APOB and PCSK9, and less frequently LDLRAP1, APOE, STAP1, LIPA, and ABCG5/8.  
 After demonstrating that bioinformatic tools could be applied to NGS data for the 
detection of CNVs in Chapter 2, we now had the ability to extend CNV analysis beyond 
the commonly studied LDLR gene and into all secondary FH-associated genes present on 
a given NGS panel. In the case of LipidSeq, this includes APOB, PCSK9, LDLRAP1, 
APOE, STAP1, LIPA and ABCG5/8 – genes in which only a limited number of small-
scale variants have so far been described in FH cases (Calandra et al., 2017).  
 Although causative CNVs in these genes are expected to be rare, they have 
nevertheless remained completely uninvestigated in FH since MLPA methods are either 
not available or not applied for genes outside of LDLR. Extending CNV analysis to all  
FH-associated genes furthers our ability to account for all genetic abnormalities capable 
of explaining FH cases; this in turn further decreases the potential for false-negative 
findings during the course of genetic diagnosis. 
 Here, we performed novel CNV analysis in FH associated genes APOB, PCSK9, 
LDLRAP1, APOE, STAP1, LIPA, and ABCG5/8 to determine the potential for previously 
overlooked CNVs to be implicated in FH cases. In 704 FH samples, we identified a 
whole-gene duplication of PCSK9 in two unrelated FH index cases; this PCSK9 CNV 
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was also found to cosegregate with affected status in family members. This finding was 
associated with a profound FH phenotype in affected individuals, and the highest known 
plasma PCSK9 level reported in a human. We found no CNVs in APOB, LDLRAP1, 
APOE, STAP1, LIPA, or ABCG5/8 in our cohort of 704 FH individuals. 
 
 
 Materials and Methods 
 
 
3.2.1 Study subjects 
 
We increased our cohort size from 388 (studied in Chapter 2) to 704 patients. All patients 
had at least “possible FH” according to validated clinical criteria. This cohort included 
429 samples from individuals referred to London Health Sciences Centre, University 
Hospital (London, ON, Canada) for treatment of severe hypercholesterolemia, plus 275 
samples sent by collaborating physicians for genetic analyses. Our protocol was approved 
by the Western University Research Ethics Board (No. 07920E) and all individuals 
provided informed consent for genetic analyses.  
 
3.2.2 Targeted next-generation sequencing (NGS) 
 
Targeted NGS was performed using our LipidSeq panel, comprised of 73 lipid 
metabolism-related genes including all specified non-LDLR FH-associated genes, namely 
APOB, PCSK9, LDLRAP1, APOE, STAP1, LIPA, and ABCG5/8. Details of our NGS 
protocol are as previously described above in Chapter 2, Methods section 2.2.2.  
 
3.2.3 Whole-exome NGS 
 
Whole-exome sequencing (WES) was performed in two CNV-positive index cases at the 
London Regional Genomics Centre (London ON, Canada). Library preparation was 
performed using the TruSeq Rapid Exome kit (Illumina) and enriched samples were 
sequenced on the Illumina NextSeq500 using 2 x 150 bp paired-end chemistry. 
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Bioinformatic analysis of raw sequencing data was performed using a custom automated 
workflow in CLC Genomics Workbench, as described above. This WES method has an 
average DOC of 125-fold per base. 
 
 
3.2.4 NGS CNV analysis 
 
CNV screening of NGS data was performed using the bioinformatic tool VarSeq CNV 
Caller (v1.4.3; Golden Helix, Bozeman, MT). The methodology and criteria used to call 
CNVs in genes of interest were described above in detail in Chapter 2, Methods section 
2.2.4 and 2.2.5. VarSeq CNV analysis was applied to both our targeted NGS (LipidSeq) 
and WES data.  
 
3.2.5 CNV confirmation by microarray analysis 
 
Confirmation in two CNV-positive index cases was performed using the CytoScan HD 
Array (ThermoFisher Scientific, Waltham, MA, USA). The array has > 1.9 million non-
polymorphic probes and > 750,000 single nucleotide polymorphism (SNP) probes. Only 
the CNV-containing genomic region was evaluated in each sample. The microarray was 
performed at Victoria Hospital (London ON, Canada) in accordance with manufacturer 
protocol. Data were analyzed using the Chromosome Analysis Suite (ChAS) version 3.2 
(ThermoFisher Scientific). The signal patterns were compared with normal in silico 
reference data built in the ChAS software. Copy number loss or gain was visualized by 
log2 ratio (sample intensity/expected reference intensity). 
 
3.2.6 Plasma PCSK9 analysis 
 
Plasma PCSK9 levels were assessed in CNV-positive index case A by both an enzyme-
linked immunosorbent (ELISA) and immunoprecipitation assay. ELISA (CircuLex) was 
performed on EDTA-plasma according to manufacturer’s protocol (MBL International, 
Woburn, MA, USA), and repeated in triplicate. Immunoprecipitation was performed on 
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10 µL of EDTA-plasma (case) or 50 µL (normal control) aliquots that were diluted into 1 
mL of buffer A (20 mM Hepes-KOH, pH 7.4, 100 mM NaCl, 1.5 mM MgCl2, 1 mM 
CaCl2, 1% NP-40) containing 2 mM PefaBloc (Roche, Basel, Switzerland) and 
precipitated overnight at 4°C using an in-house rabbit polyclonal anti-serum (Ab 1697) 
raised against full-length recombinant human PCSK9 and captured using goat anti-rabbit 
IgG-conjugated agarose beads (Rockland). The beads were washed three times with 
buffer A and eluted in SDS loading buffer (50 mM Tris-HCl, pH 6.8; 1% SDS; 5% 
glycerol; 10 mM EDTA; 0.0032% bromophenol blue, 2.5% (v/v) 2-mercaptoethanol). 
Immunoprecipitated proteins were subjected to 8% SDS-PAGE, transferred to 
nitrocellulose membrane (Bio-Rad) and incubated with primary anti-PCSK9 mouse 
monoclonal antibody (15A6). Infrared dye (IRDye-800)-labeled secondary antibody was 
used for detection on a LI-COR Odyssey infrared system (LI-COR Biosciences).  
 
3.2.7 Statistical analysis 
 
Analyses of demographic features were performed in SAS version 9.1 (SAS Institute, 
Cary NC). Discrete traits were compared using chi-square analysis, typically 2 X 2 
contingency analyses, while quantitative traits were compared using unpaired t-tests. The 
nominal level of statistical significance was set at P < 0.05. 
 
 
 
 Results 
 
 
3.3.1 Study sample demographics 
 
Baseline clinical and biochemical traits of our cohort individuals are described in Table 
3.1.  
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Table 3.1. FH cohort patient demographics. 
 Overall 
(N=704) 
Women 
(N=370) 
Men 
(N=334) 
Age, years 50.5  15.9 52.6  16.2 47.7  15.0 
Body mass index, kg/m2 28.1  5.69 27.5  5.84 28.9  5.39 
Total cholesterol, mmol/L 8.88  2.38 9.09  2.63 8.59  1.97 
LDL cholesterol, mmol/L 6.7  2.22 6.86  2.47 6.48  1.81 
HDL cholesterol, mmol/L 1.37  0.49 1.44  0.38 1.29  0.6 
Triglyceride, mmol/L 2.02  1.35 1.88  1.11 2.21  1.61 
 
Values are represented as mean ± standard deviation. Complete demographic data available 
from 429 individuals.  
 
 
3.3.2 Targeted NGS data CNV analysis 
 
In screening our LipidSeq dataset for CNVs in FH-associated genes outside of LDLR, we 
detected a large-scale duplication encompassing the entire PCSK9 gene in two FH index 
cases: hereafter termed index cases “A” and “B”. Located on chromosome 1p32, the 
human PCSK9 gene is ~25 kilobases (kb) long and is comprised of 12 exons. Sample 
outputs for each index case are shown in Figures 3.1A and 3.2A. We detected no CNVs 
in APOB, LDLRAP1, APOE, STAP1, LIPA and ABCG5/8 in this cohort of 704 FH 
individuals. 
  
3.3.3 Whole-exome CNV analysis 
 
To determine whether the large-scale duplication encompassing PCSK9 extended beyond 
the PCSK9 locus and into flanking genes we performed WES in both index cases and 
applied subsequent bioinformatic CNV analysis. In index cases A and B the genes 
flanking PCSK9 – 5’ BSND (upstream), and 3’ USP24 (downstream) - were unaffected. 
Sample outputs are shown in Figures 3.1B and 3.2B.  
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Ratio: 1.0 Ratio: 1.5 
Z-score threshold: 5.0 
Diploid Diploid Duplicate 
USP24 
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Figure 3.1. NGS-based detection of a PCSK9 CNV in a patient with FH (index case A).  
(A) Targeted NGS output: duplication of all 12 exons of the PCSK9 gene, plus 
rs11206510 probe 8655 bases upstream of PCSK9. Different regions of the output are as 
follows. i) Normalized ratio metric computed for each NGS probe target region in 
PCSK9; depth of sequence coverage comparative to reference controls. ii) Normalized z-
score metric; number of standard deviations the depth of coverage is from the reference 
control mean coverage. iii) Called CNV state per probe target region, determined by ratio 
and z-score metrics together with supporting evidence from variant allele frequencies 
(not shown). iv) Multiple affected target regions merged by segmentation analysis to call 
a contiguous duplication event. v) Exon map of PCSK9 gene. vi) LipidSeq probe target 
regions. (B) Whole-exome sequencing (WES) output: validation of PCSK9 whole-gene 
duplication, plus flanking genes BSND (5’) and USP24 (3’) unaffected (diploid). Panel 
regions i) – iv) are as in (A). v) Exon map of PCSK9 and flanking genes. vi) WES probe 
target regions. 
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Figure 3.2. NGS-based detection of a PCSK9 CNV in a patient with FH (index case B).  
(A) Targeted NGS output: duplication of all 12 exons of the PCSK9 gene, plus 
rs11206510 probe 8655 bases upstream of PCSK9. (B) Whole-exome sequencing output: 
validation of PCSK9 whole-gene duplication, plus flanking genes BSND (5’) and USP24 
(3’) unaffected (diploid). All panel regions are as in Figure 3.1. 
 
 
 
Ratio: 1.0 Ratio: 1.5 
Z-score threshold: 5.0
 
Diploid Diploid Duplicate 
USP24 
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3.3.4 CNV confirmation 
 
Microarray-array based CNV analysis performed in FH index cases A and B confirmed 
the presence of whole-gene PCSK9 duplications, while adjacent genes were unaffected. 
The array allowed for further fine mapping; the total size of this CNV duplication was 
predicted to be ~ 35 kilobases. Sample outputs are shown in Figure 3.3. 
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Figure 3.3. Microarray-based confirmation of a PCSK9 CNV in two patients with FH. 
(A) Index case A. Array output: Copy number of 3 for PCSK9 gene plus probes located 
~10 kilobases upstream of PCSK9; flanking genes BSND (5’) and USP24 (3’) unaffected. 
(B) Index case B. Array output: Copy number of 3 for PCSK9 gene plus probes located 
~10 kilobases upstream of PCSK9; flanking genes BSND (5’) and USP24 (3’) unaffected. 
Panel regions of the output are as follows. i) Log2 ratio; per probe on the array, 
calculated as sample hybridization intensity compared to expected reference intensity. ii) 
Called copy number state. 
 
 
3.3.5 Case presentations 
 
3.3.5.1  Index case A 
 
Index case A is a male of Northern European descent who was first treated for severe 
hypercholesterolemia at age 37 in 2013. He presented with an untreated LDL-C of 14.9 
mmol/L, tendon xanthomata, and extensive atherosclerosis with angina symptoms. He 
was found to have severe multi-vessel coronary artery disease (CAD), with 95%, 99% 
and 60% occlusions in left main, circumflex and right coronary arteries, respectively, and 
100% occlusion of the first diagonal branch of the left anterior descending coronary 
artery. He underwent urgent three-vessel coronary arterial bypass graft (CABG) surgery. 
His initial response to high-intensity statin therapy was poor, with < 20% LDL-C 
reduction from baseline values. Addition of ezetimibe 10 mg daily to atorvastatin (statin) 
80 mg daily reduced the LDL-C to 9.7 mmol/L (i.e. a 34.8% reduction from baseline). 
Serial bi-weekly plasmapheresis treatments were more effective, with mean post-
apheresis total cholesterol of 2.8 mmol/L; however, these treatments were discontinued 
after several months due to poor venous access. Addition of alirocumab (PCSK9 
inhibitor) 150 mg subcutaneously every 2 weeks reduced LDL-C to 6.8 mmol/L (i.e. an 
incremental 29.9% reduction from the value on statin plus ezetimibe), and a similar 
response was noted when alirocumab was switched to evolocumab (PCSK9 inhibitor) 
140 mg subcutaneously every 2 weeks. Most recently, evolocumab dose was increased to 
420 mg subcutaneously every 2 weeks, reducing LDL-C to 5.5 mmol/L (a further 19.1% 
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reduction, or a 43.3% reduction compared to statin plus ezetimibe treatment alone). In 
2015, initial LipidSeq NGS analysis followed by CNV analysis in LDLR by MLPA 
showed no causative variants.  
 His father had a historical untreated total cholesterol level of ~ 15 mmol/L with a 
similar attenuated response to statin treatment. He underwent CABG at age 50 years. 
Index case A also reported premature cardiovascular disease in second degree paternal 
relatives. His mother's untreated total cholesterol was 6.0 mmol/L. His asymptomatic 13-
year-old daughter had serum total cholesterol of 9.5 mmol/L, triglycerides (TG) of 0.6 
mmol/L; LDL-C of 7.5 mmol/L; and HDL-C of 1.78 mmol/L. 
 
3.3.5.2 Index case B 
 
Index case B is a male of Northern European descent, not known to be related to index 
case A, who was referred at age 40 with refractory, severe hypercholesterolemia, which 
was first diagnosed at age 25 years. His historical untreated LDL-C was 14.5 mmol/L. He 
was asymptomatic from cardiovascular and metabolic perspectives. He had diffuse 
xanthomatosis, involving finger extensor, Achilles and plantar flexor tendons bilaterally. 
With rosuvastatin 40 mg daily and ezetimibe 10 mg daily, his lowest recorded LDL-C 
level was 4.32 mmol/L, but typically this level ranged between 5.5 and 7.0 mmol/L on 
treatment. PCSK9 inhibition was never initiated before he was lost to follow-up due to 
work-related relocation. His family history was strongly positive for 
hypercholesterolemia. His father suffered a stroke at age 55 and had bilateral lower limb 
amputations in the seventh decade of life. His mother had hypercholesterolemia and 
underwent 4-vessel CABG at age 62. His maternal grandfather died at age 40 of a 
myocardial infarction. His 10 year-old son was reported to have hypercholesterolemia. 
 His older sister, younger brother and younger sister all had severe 
hypercholesterolemia; all received high-intensity statin and ezetimibe. His younger sister 
was assessed at age 38 after having been diagnosed with hypercholesterolemia at age 31. 
Her highest recorded untreated LDL-C level was 11.4 mmol/L. A lifelong cigarette 
smoker, she continued to smoke one pack daily even after her hypercholesterolemia 
diagnosis. On examination, she had bilateral xanthelasmas and diffuse pronounced 
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xanthomatosis, involving finger extensor and Achilles tendons bilaterally. At age 35 she 
developed left lower limb claudication, with diffuse femoral atherosclerosis demonstrated 
angiographically. With rosuvastatin 40 mg daily and ezetimibe 10 mg daily, her lowest 
recorded LDL-C level was 6.12 mmol/L, but typically this level ranged between 7 and 8 
mmol/L on treatment. Her 11 year-old son was also reported to have 
hypercholesterolemia. Before PCSK9 inhibitors became available, she died at age 42 of a 
myocardial infarction. Initial LipidSeq NGS analysis of both siblings in 2014 followed by 
CNV analysis in LDLR using MLPA found no causative variants to explain their 
phenotype. 
 
3.3.6 Co-segregation analysis 
 
We next obtained DNA samples from family members of index case A and performed 
targeted NGS-based CNV analysis using LipidSeq. Both the affected father and affected 
daughter of index case A (described above) were positive for this PCSK9 duplication, 
while the unaffected mother was CNV negative. The above-described affected sister of 
index case B was also one of our FH patients; her DNA was available for analysis and 
was found to be CNV positive. No additional family members of index case B were 
available for analysis. Pedigrees are shown in Figure 3.4. NGS-based sample outputs for 
index case family members are shown in  Figure 3.5 – 3.8. 
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Figure 3.4. Family pedigree of two FH index cases with a whole-gene duplication of 
PCSK9. Males and females are represented as squares and circles, respectively, while 
black-shaded and un-shaded represents individuals with reported severe 
hypercholesterolemia and normal lipid profiles, respectively. Enlarged shapes refer to 
individuals where a DNA sample was possible to obtain and analyze for the presence (+) 
or absence (-) of a PCSK9 copy number variation (CNV). Grey diagonal lines indicate 
deceased. Roman numerals I-IV indicate generation. MI, myocardial infarction; CABG, 
coronary arterial bypass graft. 
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Figure 3.5. Targeted NGS-based CNV assessment of PCSK9 in an individual with FH 
(affected father of index case A). Targeted NGS output: duplication of all 12 exons of the 
PCSK9 gene, plus rs11206510 probe 8655 bases upstream of PCSK9. Different regions 
of the output are as follows. i) Normalized ratio metric computed for each NGS probe 
target region in PCSK9; depth of sequence coverage comparative to reference controls. ii) 
Normalized z-score metric; number of standard deviations the depth of coverage is from 
the reference control mean coverage. iii) Called CNV state per probe target region, 
determined by ratio and z-score metrics together with supporting evidence from variant 
allele frequencies (not shown). iv) Multiple affected target regions merged by 
segmentation analysis to call a contiguous duplication event. v) Exon map of PCSK9 
gene. vi) LipidSeq probe target regions. 
 
 
 
 
 
 
Ratio: 1.0 
Ratio: 1.5 
Z-score threshold: 5.0 
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Figure 3.6. Targeted NGS-based CNV assessment of PCSK9 in an individual with FH 
(affected daughter of index case A).  Targeted NGS output: duplication of all 12 exons of 
the PCSK9 gene, plus rs11206510 probe 8655 bases upstream of PCSK9. 
 
 
 
Figure 3.7. Targeted NGS-based CNV assessment of PCSK9 in an individual without FH 
(unaffected mother of index case A). Targeted NGS output: unaffected (diploid) PCSK9 
gene. 
  
Z-score: 0 
Ratio: 1.0 
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Figure 3.8. Targeted NGS-based CNV assessment of PCSK9 in an individual with FH 
(affected sister of index case B). Targeted NGS output: duplication of all 12 exons of the 
PCSK9 gene, plus rs11206510 probe 8655 bases upstream of PCSK9.  
 
 
 
3.3.7 Plasma PCSK9 levels 
 
Plasma PCSK9 in index case A was ~ 5000 ng/ml as determined by ELISA; this was a ~ 
21-fold increase compared to a normal control (Figure 3.9A). Immunoprecipitation and 
immunoblot analysis confirmed that the observed increase corresponded to full-length 
PCSK9 (Figure 3.9B) and not a furin-cleaved inactive form (Benjannet et al., 2006) . 
Plasma samples from index case B or affected relatives were not available for analysis.  
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Figure 3.9. Plasma PCSK9 level in a FH patient (index case A) with a PCSK9 whole-
gene duplication. (A) Plasma PCSK9 enzyme-linked immunosorbent assay (ELISA) 
measurement (repeat n=3). (B) Plasma PCSK9 immunoprecipitation. PCSK9 was 
immunoprecipitated from EDTA-plasma using a rabbit polyclonal antibody raised against 
full-length recombinant human PCSK9 and detected with a monoclonal antibody (15A6). 
For comparison to normolipidemic control, plasma from FH patient (index case A) was 
diluted 5-fold prior to immunoprecipitation analysis.  
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 Discussion  
 
 
In this study, we used a NGS bioinformatic approach to perform novel CNV screening in 
FH-associated genes outside of the commonly studied LDLR. In a large cohort of 704 FH 
individuals we detected a whole-gene duplication of PCSK9 in two index cases and no 
CNVs in APOB, LDLRAP1, APOE, STAP1, LIPA, or ABCG5/8.  
 PCSK9 is a serine protease that governs net LDLR activity. Secreted mainly by 
the liver, PCSK9 binds the LDLR at the cell surface, and following endocytosis of the 
LDLR-PCSK9 complex, diverts LDLR toward lysosomes for degradation, thus short 
circuiting the normal recycling of the receptor to the cell surface (Zhang et al., 2007). 
Variants causing a gain of function (GOF) in PCSK9 enhance LDLR degradation, 
resulting in elevated plasma LDL-C. Genetic analysis of atypical FH patients initially led 
to the discovery of PCSK9’s role in LDLR recycling and cholesterol homeostasis; in 
2003 Abifadel et al. identified two GOF missense variants, p.Ser127Arg and 
p.Phe216Leu, in three French families with autosomal dominant FH (Abifadel et al., 
2003). Since then, about 30 different PCSK9 variants, many with distinct GOF 
mechanisms, have been described throughout all domains of the protein (Dron & Hegele, 
2017). To date, however, these have all been small-scale variants – namely 24 missense, 
2 splicing, 2 tri-nucleotide indels, and a 5’UTR substitution. The large-scale whole-gene 
duplication identified here, causing an increase in gene dosage, constitutes a novel GOF 
mechanism described for PCSK9 in FH. 
 The severity of the FH phenotype in the index cases and their affected relatives is 
notable. In particular, untreated LDL-C levels ranged between 11.0 and 15.0 mmol/L, 
with prominent xanthomatosis and atherosclerotic cardiovascular disease presenting in 
the fourth decade of life, specifically 4-vessel CABG in index case A and myocardial 
infarction in index case B relatives. LDL-C levels elevated to this degree are more 
characteristic of homozygous FH, however, both NGS-based and microarray-based CNV 
analysis confirm that only a single PCSK9 allele was affected in both families, with 
overall copy number increasing from two (diploid) to three.  
 Thus, a single extra copy of PCSK9 seems to profoundly affect LDL-C 
homeostasis, underlying a severe form of FH. However, the phenotypic outcome of any 
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gene duplication depends on several factors, including the location and orientation of the 
duplicated genomic material. In other disorders, there is evidence to suggest most large-
scale duplications occur in tandem (Newman et al. 2015), however, it is possible that the 
duplicated material is present elsewhere in the genome. The expression of a duplicated 
gene depends on genomic location and its epigenetic regulation. One caveat of using 
exome-based NGS CNV analysis, as well as microarray-based CNV analysis, is that 
while duplicated material can be detected, its precise location and orientation are not 
always defined.  
 This PCSK9 CNV is associated with a plasma PCSK9 measurement of ~5000 
ng/ml, a 21-fold increase compared to a normal control. Although variability in ELISA-
based protocols make comparisons with values from other studies difficult, this is 
nonetheless by many-fold the highest known human level reported. This finding supports 
the functionality of this particular CNV event – i.e. the duplicated material is actively 
expressed.  
 Other factors might have influenced plasma PCSK9 levels in index case A, 
including high baseline LDL-C levels and statin treatment. For instance, plasma PCSK9 
levels positively correlate with LDL-C; for LDL-C levels typically seen in HoFH (i.e. 
LDL-C >13.0 mmol/L, as seen in the index cases reported here), baseline plasma PCSK9 
levels are 2- to 3-fold higher than normolipidemic controls (Cameron et al., 2012; 
Drouin-Chartier et al., 2015; Raal et al., 2013). Also, statins upregulate PCSK9 
expression; the PCSK9 promoter contains a sterol regulator element (SRE) site and is co-
expressed with LDLR following nuclear translocalization of SREBP-2 in response to low 
intracellular cholesterol (Dubuc et al., 2004). Index case A remained on rosuvastatin 40 
mg daily while plasma was taken for PCSK9 determination. Typically, administration of 
a high-intensity statin is associated with a 25–50% increase in plasma PCSK9 levels 
(Nozue, 2017). Raal et al. showed that rosuvastatin 40 mg daily resulted in a 37% 
increase in plasma PCSK9 levels (Raal et al., 2013). The effect of statins on PCSK9 
expression might be amplified when an extra copy of PCSK9 is present. However, 
despite both the high background LDL-C and high-intensity statin therapy in index case 
A, the observed 21-fold increase in plasma PCSK9 is still disproportionately high. It is 
possible that the duplicated PCSK9 gene in this patient may be located elsewhere in the 
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genome, perhaps driven by an unknown enhancer element, or resides in a genomic region 
where transcription is continually active (i.e. in a euchromatic state), resulting in an 
increased rate of expression and thus high PCSK9 levels. 
 Given the CNV-detection methodologies used here, the exact location of the 
PCSK9 duplication within the genome is not known. This limits the ability to determine 
whether the same ancestral CNV event is present in both families, and also to speculate 
on possible gene expression influences which may explain the disproportionately high 
PCSK9 level detected. 
  These findings have therapeutic implications. As statin-induced upregulation of 
PCSK9 may be accentuated in patients with an extra copy of PCSK9, high-dose statin 
therapy may have only limited efficacy. Indeed, there was resistance to intensive statin 
therapy in both index cases and in several family members. With plasma PCSK9 levels 
increased, index case A also appeared to require a high dose of a PCSK9 inhibitor.  
 In addition, we found no CNVs in APOB, LDLRAP1, APOE, STAP1, LIPA, or 
ABCG5/8 in this cohort of 704 FH individuals. It is possible that pathogenic CNVs in 
these other FH-related genes exist, but may require larger FH cohorts to be detected. The 
potential of finding CNVs in these genes is of interest since ~20-40% of patients with 
suspected FH in many clinical cohorts have no apparent "typical" or obvious genetic 
aberrations underlying their phenotype. Evaluating SNPs to define a possible polygenic 
basis for hypercholesterolemia may explain an additional ~20% of clinically ascertained 
FH cases (Wang et al., 2016), but still leaves a substantial number of "unexplained" 
cases. Systematic screening in additional populations could help evaluate the possibility 
that CNVs in other FH-related genes may be present in some FH subjects.  
 
 
 Conclusion 
 
In conclusion, we performed novel CNV screening in FH-associated genes in a large 
cohort of 704 FH individuals, and identified a whole-gene PCSK9 duplication in two FH 
index cases and no CNVs in APOB, LDLRAP1, APOE, STAP1, LIPA, or ABCG5/8. This 
is the first report of a PCSK9 CNV associated with a severe FH phenotype and 
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profoundly elevated plasma PCSK9. The grossly elevated PCSK9 level may limit the 
efficacy of intensive statin therapy and perhaps also the efficacy of PCSK9 inhibition. 
These findings also highlight the potential for finding novel disease-causing variants 
when CNV screening is extended beyond the commonly studied LDLR gene, and may 
help to further avoid false-negative genetic diagnoses and direct treatment strategy. 
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Chapter 4 – ClinVar database: data sharing to improve 
interpretation of genetic variants identified in FH patients 
worldwide 
 
4  
Chapter 4 was adapted from the independent study “ClinVar database of global familial 
hypercholesterolemia-associated DNA variants”, published in Human Mutation in 2018 
(Iacocca et al., 2018; PMID: 30311388). w 
 
 Introduction 
 
Successful genetic diagnosis hinges on the ability of a diagnostic laboratory to accurately 
interpret detected DNA variants as “pathogenic” or “benign” – a challenging task when 
considering there are often dozens or more rare DNA variants identified during the 
course of NGS sequence analysis. Since genetic analysis in FH began in the 1970s, a vast 
number of DNA variants have been identified in patients, primarily within LDLR, and 
more recently in APOB and PCSK9. 
Interpreting the clinical significance of genetic variants is challenging, and often 
multifaceted, however, can be greatly improved when there is information on variants 
from multiple independent sources which can be shared among laboratories. A data-
sharing culture is not new among the FH field; for years the Leiden Open Source 
Variation Database (LOVD) has served as a publicly available FH-variant repository, 
hosting 1707 unique LDLR variants as of 2016 (Leigh et al., 2017). However, ClinVar, an 
NCBI-funded resource, has since emerged as the primary centralized database for 
archiving clinically relevant variants for many Mendelian diseases (Landrum et al., 
2014). ClinVar facilitates a much more comprehensive approach to both the 
consolidation and presentation of patient and molecular data, and includes a multitude of 
interconnected resources to aid in improving variant interpretation (Harrison et al., 2016).  
Here, I present the recent efforts made by the Clinical Genome (ClinGen) 
Resource consortium, along with various global FH researchers, to update the number 
and characterization of FH variants hosted by ClinVar. I specifically reviewed, 
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standardized, and submitted data on 369 FH-associated variants identified in Dr. Robert 
Hegele’s laboratory to ClinVar (4th largest single-center variant contribution globally), 
and following submission efforts, co-lead data analysis of all 6,651 FH-associated 
variants submitted worldwide. In doing this, I also identified multiple areas for 
improvement to further reform the interpretation of FH-associated variants in the future. 
 
 
 
 Materials and Methods 
 
 
4.2.1 ClinGen FH Variant Curation Expert Panel 
 
The ClinGen FH Variant Curation Expert Panel (FH VC-EP) is composed of >20 
members (Table 4.1). Members were selected on the basis of achieving a balanced 
representation of expert clinicians, clinical laboratory diagnosticians, researchers, and 
genomic medicine specialists. An emphasis was also placed on global representation, 
with members from the United States, Brazil, United Kingdom, Netherlands, France, 
Portugal, Czech Republic, Spain, Israel, Australia and Canada. The FH VC-EP is part of 
the ClinGen Cardiovascular Clinical Domain Working Group. 
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Table 4.1. ClinGen FH Variant Curation Expert Panel members. 
Name Institution Area and Type of Expertise Role 
Joshua W. 
Knowles, MD, PhD 
Stanford University & 
FH Foundation, USA 
Clinician/Researcher/Laboratory 
Director 
Executive 
Leader 
Mafalda Bourbon, 
PhD 
Instituto Nacional de 
Saúde Doutor Ricardo 
Jorge, Portugal 
Researcher/Laboratory Director Executive 
Leader 
C. Lisa Kurtz, PhD University of North 
Carolina, Chapel Hill, 
USA  
Researcher Coordinator 
Robert A. Hegele, 
MD 
Robarts Research 
Institute, Western 
University, Canada 
Clinician/Researcher/Laboratory 
Director 
Executive 
Committee 
Eric J. Sijbrands, 
MD, PhD 
Erasmus University, 
Netherlands 
Clinician/Researcher/Laboratory 
Director 
Executive 
Committee 
Alain Carrie, MD, 
PhD 
Pitié-Salpêtrière 
University Hospital, 
France 
Researcher/Laboratory Director Executive 
Committee 
Joep C. Defesche, 
PhD 
Academic Medical 
Center, University of 
Amsterdam, Netherlands 
Researcher/Laboratory Director Executive 
Committee 
Tomas Freiberger, 
MD, PhD 
University Hospital 
Brno, Czech Republic  
Researcher/Laboratory Director Executive 
Committee 
Sarah E. Leigh, 
PhD 
Genomics England, 
United Kingdom 
Researcher Executive 
Committee 
Amanda J. Hooper, 
PhD 
PathWest Laboratory 
Medicine, University of 
Western Australia 
Researcher/Laboratory Director Expert 
Steve E. 
Humphries, PhD 
University College of 
London, United 
Kingdom 
Researcher/Laboratory Director Expert 
Amit V. Khera, 
MD 
Broad Institute & 
Massachusetts General 
Hospital, USA 
Clinician/Researcher Expert 
Michael Murray, 
MD 
Geisinger, USA Clinician/Researcher/Director of 
Clinical Genomics 
Expert 
Jean-Pierre Rabes, 
MD, PhD 
Hôpital Ambroise Paré, 
France 
Clinician/Researcher/Laboratory 
Director 
Expert 
Daniel Rader, MD University of 
Pennsylvania, USA 
Clinician/Researcher/Scientific 
Director 
Expert 
Raul Santos, MD, 
PhD 
InCor, São Paulo 
University, Brazil 
Clinician/Researcher/Scientific 
Director 
Expert 
Marianne Stef, PhD Progenika/Grifols, USA Researcher/Laboratory Director Expert 
Marina Cuchel, 
MD, PhD 
University of 
Pennsylvania, USA 
Clinician/Researcher/Laboratory 
Director 
Expert 
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Mariko Harada-
Shiba, MD, PhD 
National Cerebral and 
Cardiovascular Center 
Research Institute, Japan 
Clinician/Researcher/Laboratory 
Director 
Expert 
Margaret Chen, 
PhD, FACMG 
GeneDx, USA Researcher/Laboratory Director Expert 
Ronen Durst, MD Hadassah Hebrew 
University Medical 
Center, Israel 
Clinician/Researcher/Laboratory 
Director 
Expert 
Pedro Mata, MD, 
PhD 
Fundacion 
Hipercolesterolemia 
Familiar, Spain 
Clinician/Researcher/Laboratory 
Director 
Expert 
Joana R. Chora, 
MSc 
Instituto Nacional de 
Saúde Doutor Ricardo 
Jorge, Portugal 
PhD student Curator 
Michael A. Iacocca, 
BSc 
Robarts Research 
Institute, Western 
University, Canada 
MSc student Curator 
Lukas Tichy, PhD University Hospital 
Brno, Czech Republic 
Post doctorate researcher Curator 
 
 
  
4.2.2 Variant submission to ClinVar 
 
Starting in 2016, several sources were recruited for consolidation of FH-associated 
variants into ClinVar. These efforts were facilitated by the FH Foundation working with 
ClinGen leadership to convene a session of interested parties, including members of the 
FH VC-EP at the 2016 international FH Summit in Dallas, USA, and 2017 in Miami, 
USA. First, FH VC-EP members began submitting FH-associated variants and variant-
level data from their respective internal databases to ClinVar. We then encouraged global 
colleagues to submit internally stored FH-associated variants, with a focus on the largest 
remaining sequencing centers from various countries and jurisdictions. Further, we 
facilitated variant transfer from existing centralized databases, namely LOVD 
(https://databases.lovd.nl/shared/genes/LDLR). 
Submitters followed a standard protocol for submission. They were required to 
register their organization/center on the ClinVar Submission Portal 
(https://submit.ncbi.nlm.nih.gov/clinvar/). Following ClinVar approval, variant 
submissions were performed using the Submission Template spreadsheet 
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(https://www.ncbi.nlm.nih.gov/clinvar/docs/submit/). Submitted variants required 
standardized annotation (HGVS expression or chromosomal coordinate change), 
associated condition, interpretation of clinical and/or functional significance, 
interpretation criteria, collection method (clinical testing or research), allele origin 
(germline or somatic), and individual affected status. A wide range of additional variant-
level data types were optional for inclusion, such as number of variant observations, 
ethnicity and/or geographic origin of the individual, cosegregation/family data, functional 
data, phenotypic information, and/or normolipidemic screening results. 
  
4.2.3 ClinVar variant analysis 
 
Following submission efforts, ClinVar Miner (https://clinvarminer.genetics.utah.edu/) 
was used to extract variant-level data from the ClinVar database for LDLR, APOB, and 
PCSK9. Variants that did not have a submitted disease association of “Familial 
hypercholesterolemia” or accepted alternative term were removed manually, specifically: 
“Familial hypobetalipoproteinemia” (n=221), “Hypercholesterolemia, autosomal 
dominant, type B; Hypobetalipoproteinemia, familial, 1” (n=156; entry of two opposing 
conditions per single individual), “Low density lipoprotein cholesterol level quantitative 
trait locus 1” (n=3), “hypocholesterolemia” (n=2), “Hypobetalipoproteinemia, familial, 
1” (n=2), “Early-onset coronary artery disease (CAD)” (n=2; removed as other 
dyslipidemias/morbidities can lead to CAD), “Hypobetalipoproteinemia” (n=1), 
“C0950123: Inborn genetic diseases” (n=1), “not specified” (n=191), and “not provided” 
(n=164). Variant consequences were determined manually from DNA and protein level 
variant information and confirmed using the Mutalyzer Name Checker batch tool v.2.0.28 
(Leiden University Medical Center, Netherlands; https://mutalyzer.nl/). 
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 Results 
 
 
4.3.1 Global ClinVar submission 
 
Prior to 2016, there were 242 (193 unique) LDLR, 63 (59) APOB and 26 (26) PCSK9 
variant submissions present in ClinVar. In a concerted effort to increase this number, the 
ClinGen FH VC-EP encouraged the submission of FH-associated variants by colleagues 
and sequencing centers on a global scale. As a result, the number of FH-associated 
submissions now residing in the ClinVar database increased ~ 18-fold and is summarized 
in Table 4.2. Additionally, there are 201 LDLR, 423 APOB, and 119 PCSK9 variant 
submissions that do not have a disease association of FH and were removed from 
analysis. A total of 30 centers from 13 different countries have submitted FH-associated 
variants to ClinVar. Submitting center totals are listed per gene in Table 4.3.  
 
 
Table 4.2. Number of variants submitted to ClinVar by gene. 
 LDLR APOB PCSK9 Total 
All variants submitted to ClinVar 5174 1003 474 6651 
Variants detected in FH patients 4973 580 355 5908 
Unique variants detected in FH patients 2314 353 216 2883 
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Table 4.3. Centers that submitted FH-associated variants to ClinVar. 
Submitting Centers Country LDLR APOB PCSK9 Total 
LDLR-Leiden Open Source Variation Database, 
British Heart Foundation 
United 
Kingdom 
1670 - - 1670 
Laboratory of Molecular Diagnostics, Vascular 
Medicine, Academic Medical Centre, University 
of Amsterdam 
Netherlands 686 25 46 757 
Centre of Molecular Genetics, Obesity and 
Dyslipidemias Unit, Pitié-Salpêtrière University 
Hospital 
France 414 1 19 434 
Cardiovascular Research Group, National 
Institute of Health Dr. Ricardo Jorge 
Portugal 276 53 70 399 
Blackburn Cardiovascular Genetics Laboratory, 
Robarts Research Institute, Western University 
Canada 202 137 30 369 
Clinical Services Laboratory, Illumina USA 97 180 85 362 
Molecular Medicine of Metabolic Diseases Unit 
(U4M), University of Lille, Regional Hospital 
Center 
France 344 - - 344 
Spanish Familial Hypercholesterolemia 
Foundation 
Spain 320 10 1 331 
Laboratory of Genetics and Molecular 
Cardiology, University of São Paulo 
Brazil 201 63 16 280 
Molecular Genetics Laboratory, Centre for 
Cardiovascular Surgery and Transplantation 
Czech 
Republic 
197 - - 197 
Invitae USA 156 - 40 196 
Cardiovascular Genetics Laboratory, PathWest 
Laboratory Medicine WA 
Australia 152 - - 152 
Color Genomics USA 23 65 25 113 
Other USA, 
Germany, 
Finland, 
India, South 
Korea 
235 46 23 304 
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4.3.2  FH-associated variant characteristics 
 
Unique FH-associated variants present on ClinVar are categorized by type for LDLR, 
APOB and PCSK9 in Table 4.4 and shown by location across all exons in Figure 4.1. 
Missense variants are the most prevalent unique variant type in each of the three genes, 
followed by frameshift variants in LDLR, and synonymous variants in both APOB and 
PCSK9. In LDLR, 18% of all unique variants are located in exon 4, in APOB, 41% are in 
exon 26 and 15% in exon 29, and in PCSK9, 19% are in the 3’UTR region.  
 
Table 4.4. Unique FH-associated variants submitted to ClinVar by gene and variant type. 
Variant Type LDLR APOB PCSK9 
3'UTR 77 9 40 
5'UTR 54 4 18 
Frameshift 430 12 1 
In-frame indels 87 5 6 
Intronic 48 3 26 
Splicing 198 24 13 
CNV (deletion) 100 - - 
CNV (duplication) 42 - - 
Missense 1011 218 82 
Nonsense 179 4 1 
Synonymous 83 74 28 
Cis variants 5 - - 
Total 2314 353 216 
 
In‐frame indels: smaller than one exon; cis variants (single submission of two variants on 
same allele) include: three double missense, one in‐frame indel + frameshift, one in‐
frame indel + missense; indel, insertion or deletion; UTR, untranslated region. 
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Figure 4.1. Number of unique FH‐associated variants in ClinVar by exonic location and 
variant type.  Variants in introns are represented in the closest exon. Cis variants: single 
submission with two variants in same allele; intronic: variants outside +/−15 nucleotides 
(nts) of intron/exon border; splicing: variants known to affect splicing or variants within 
+/−15 nts of intron/exon border. CNV, copy number variation; indel, insertion or 
deletion; NA, not applicable (variants spanning more than one exon); UTR, untranslated 
region. 
 
 
 Variants submitted to ClinVar range from benign to pathogenic or can be 
submitted without an assertion; with the exception of 198 FH-associated variant 
submissions, submitting centers provided a pathogenicity classification for their variants, 
found summarized by gene in Table 4.5. Unique variants are categorized by 
classification in Table 4.6; 57.9% (1670 of 2883) of these variants have been classified 
by submitters as pathogenic or likely pathogenic (or both, in cases of multiple 
submissions for the same variant), 15.5% (448 of 2883) have been classified as a variant 
of unknown significance (VUS) and 10.4% (299 of 2883) have been classified as benign 
or likely benign. The remaining 13.1 % of variants (379 of 2883) have conflicting 
classifications using a three-tier system (Benign/Likely benign + Uncertain significance; 
or Pathogenic/Likely pathogenic + Uncertain significance; or Benign/Likely benign + 
Pathogenic/Likely pathogenic). 
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Table 4.5. Clinical significance of all FH-associated variant submissions in ClinVar, 
independent of criteria used for classification.  
Clinical significance LDLR APOB PCSK9 
Benign 205 (4.1%) 57 (9.8%) 88 (24.8%) 
Likely benign 312 (6.3%) 97 (16.7%) 54 (15.2%) 
Uncertain significance 526 (10.6%) 254 (43.8%) 132 (37.2%) 
Likely pathogenic 1525 (30.7%) 10 (1.7%) 15 (4.2%) 
Pathogenic 2351 (42.3%) 42 (7.2%) 42 (11.8%) 
Not provided 54 (1.1%) 120 (20.7%) 24 (6.8%) 
Total 4973 580 355 
 
 
Table 4.6. Clinical significance of unique FH-associated variants in ClinVar, independent 
of criteria used for classification.  
Clinical significance LDLR APOB PCSK9 
Benign/Likely benign 200 (8.7%) 44 (15.1%) 55 (26.8%) 
Uncertain significance 182 (7.9%) 171 (58.6%) 95 (46.3%) 
Pathogenic/Likely pathogenic 1614 (70.2%) 30 (10.3%) 26 (12.7%) 
Conflicting classification 303 (13.2%) 47 (16.0%) 29 (14.2%) 
Not provided 15 61 11 
Total 2314 353 216 
 
Conflicting classifications (considered for variants with multiple submissions): 
Benign/Likely benign + Uncertain significance; or Pathogenic/Likely pathogenic + 
Uncertain significance; or Benign/Likely benign + Pathogenic/Likely pathogenic. 
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4.3.3 Variant classification methods 
 
A wide range of criteria have been used to classify FH-associated variants present on 
ClinVar. These include the general American College of Medical Genetics / Association 
for Molecular Pathology (ACMG/AMP) guidelines (2015), specified guidelines adhering 
to the ACMG/AMP framework, and a number of independent methods. The most used 
method was ACMG/AMP framework classification, followed by the Association for 
Clinical Genetic Science (ACGS) guidelines used in all LOVD transferred variants; a 
large number of variants (n=865) with classifications did not have indication of criteria 
used (Table 4.7). Most variants with multiple submissions have been classified using 
various different criteria (Figure 4.2). The specific criteria used by each submitter are 
listed in Table 4.8. 
 
 
Table 4.7. Criteria used for FH-associated variant classifications in ClinVar. 
Criteria used for classification LDLR APOB PCSK9 Total 
ACMG/AMP Guidelines 1144 127 99 1370 
ACMG/AMP Framework 295 194 120 609 
ACGS Guidelines 1669 - - 1669 
Independent methods 186 26 9 221 
No criteria 793 25 47 865 
 
ACMG/AMP framework: specified criteria adhering to the ACMG/AMP framework; No 
criteria: classification given but criteria used not provided. ACGS, Association for 
Clinical Genetic Science; ACMG/AMP, American College of Medical Genetics / 
Association for Molecular Pathology. 
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Figure 4.2. Number of unique variants (n=2796) classified by different sets of criteria. 
For 87 unique variants, no classification was submitted. ACMG/AMP framework: 
specified criteria adhering to ACMG/AMP framework; No criteria: classification given 
but criteria used not provided. ACGS, Association for Clinical Genetic Science; 
ACMG/AMP, American College of Medical Genetics / Association for Molecular 
Pathology. 
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Table 4.8. Criteria for variant classification used by each submitting center. 
Submitting Centers Country Criteria 
Centre of Molecular Genetics, Obesity and 
Dyslipidemias Unit, Pitié-Salpêtrière University 
Hospital 
France ACMG/AMP Guidelines 
(Richards et al., 2015) 
Cardiovascular Research Group, National Institute of 
Health Dr. Ricardo Jorge 
Portugal ACMG/AMP Guidelines 
(Richards et al., 2015) 
Molecular Medicine of Metabolic Diseases Unit 
(U4M), University of Lille, Regional Hospital Center 
France ACMG/AMP Guidelines 
(Richards et al., 2015) 
Spanish Familial Hypercholesterolemia Foundation Spain ACMG/AMP Guidelines 
(Richards et al., 2015) 
Laboratory of Genetics and Molecular Cardiology, 
University of São Paulo 
Brazil ACMG/AMP Guidelines 
(Richards et al., 2015) 
Molecular Genetics Laboratory, Centre for 
Cardiovascular Surgery and Transplantation 
Czech 
Republic 
ACMG/AMP Guidelines 
(Richards et al., 2015) 
Color Genomics USA ACMG/AMP Guidelines 
(Richards et al., 2015) 
Knight Diagnostic Laboratories, Oregon Health and 
Sciences University 
USA ACMG/AMP Guidelines 
(Richards et al., 2015) 
Phosphorus USA ACMG/AMP Guidelines 
(Richards et al., 2015) 
Molecular Diagnostics Laboratory, Nemours Alfred I. 
duPont Hospital for Children 
USA ACMG/AMP Guidelines 
(Richards et al., 2015) 
Institute of Medical Genetics and Genomics, Sir 
Ganga Ram Hospital 
India ACMG/AMP Guidelines 
(Richards et al., 2015) 
Soonchunhyang University Medical Center South Korea ACMG/AMP Guidelines 
(Richards et al., 2015) 
Clinical Services Laboratory, Illumina USA ICSL Variant Classification 
(ACMG/AMP framework; 
(Ilumina Clinical Services 
Laboratory, 2016)) 
Invitae USA Invitae Variant Classification: 
Sherloc (ACMG/AMP 
framework; (Nykamp et al., 
2017) 
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Laboratory Corporation of America USA LabCorp Variant Classification 
Specifications (ACMG/AMP 
framework; (Laboratory 
Corporation of America, 2015)) 
Division of Human Genetics & Genomic Diagnostics, 
Children’s Hospital of Philadelphia 
USA DGD Variant Analysis 
Guidelines 
(ACMG/AMP framework; 
(Division of Genomic 
Diagnostics & The Children’s 
Hospital of Philadelphia, 2015)) 
Cardiovascular Biomarker Research Laboratory, 
Mayo Clinic 
USA Mayo Cardiovascular 
Biomarkers Research 
Laboratory LDLR variant 
Interpretation Criteria  
(ACMG/AMP framework; 
(Kullo Laboratory, 2015)) 
Blueprint Genetics Finland Blueprint Variant Classification 
(ACMG/AMP framework; 
(Blueprint Genetics, 2016)) 
LDLR-Leiden Open Source Variation Database, 
British Heart Foundation 
United 
Kingdom 
ACGS Variant Guidelines 
(Wallis, Payne, McAnulty, & 
Bodmer, 2013) 
Blackburn Cardiovascular Genetics Laboratory, 
Robarts Research Institute, Western University  
Canada Independent method; Submitters 
publication (Wang et al., 2016) 
Clinical Sequencing Exploratory Research, 
University of Washington 
USA Independent method; Literature 
(Amendola et al., 2015) 
Institute for Integrative and Experimental Genomics, 
University of Luebeck 
Germany Independent method; 
Submitter's publication (Brænne 
et al., 2016) 
Laboratory for Molecular Medicine, Partners 
HealthCare Personalized Medicine, Harvard Medical 
School 
USA Independent method; 
Submitter’s publication 
(Duzkale et al., 2013) 
SNPedia USA Independent method; Literature 
(Khera et al., 2016) 
Laboratory of Molecular Diagnostics, Vascular 
Medicine, Academic Medical Centre, University of 
Amsterdam  
Netherlands None 
Cardiovascular Genetics Laboratory, PathWest 
Laboratory Medicine WA 
Australia None 
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Online Mendelian Inheritance in Man (OMIM) USA None 
GeneReviews USA None 
Bioscience Institute for Medical Diagnostics, Sonic 
Healthcare 
Germany None 
GenomeConnect USA None 
 
ACMG/AMP, American College of Medical Genetics / Association for Molecular 
Pathology; ACGS, Association for Clinical Genetic Science. 
 
 
4.3.4 Variant-level data 
 
Some variants (n=1972 unique, 3435 submissions) were submitted with some kind of 
supporting variant-level data. This included information on patient clinical features, if 
there was family history of disease, the number of variant alleles or number of families 
with the variant identified, number of families with observed segregation, if it was an 
incidental finding and note of any related functional studies published (Table 4.9). 
However, information of co-segregation was only submitted to ClinVar for eight variants, 
and phenotype data was only submitted for 490 unique variants (in 1043 total 
submissions). Functional studies were reported for 334 unique variants (437 
submissions). 
 
 
Table 4.9. Number of unique variants with each variant-level data type available in 
ClinVar. 
Variant-level data submitted as evidence* LDLR APOB PCSK9 
Variant alleles/number of families with variant 1885 26 11 
Clinical features/Family history 490 0 0 
Incidental finding 344 0 0 
Functional study 293 19 22 
Number of families with observed segregation 8 0 0 
*Labels extracted directly from ClinVar 
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 Discussion  
 
Data sharing through a centralized open-source database is essential to achieve accurate 
and consistent interpretation of variants identified during the course of genetic testing. 
Through the concerted efforts of the ClinGen FH VC-EP, submission of FH-associated 
variants to ClinVar from different global laboratories resulted in an increase of 10 times 
the number of unique variants reported during the past years. This was only possible due 
to a common effort and willingness to share internal data, and demonstrates the power of 
collaboration across patient-groups, academic labs, commercial labs and scientific 
funding bodies.  
An extensive range of FH-associated variants are now present on ClinVar to aid 
with variant interpretation. The relative proportions of variants and variant-types per gene 
are consistent with what has been previously reported (Chora et al., 2018; Leigh et al., 
2017). However, there are more known FH-associated variants identified in LDLR, APOB 
and PCSK9 than previously thought. The FH literature has continued to cite a historical 
number of ~2000 FH-associated variants identified worldwide; however, with ~2900 
presented here, this has now become outdated.  
It is noteworthy that a number of variants with multiple submissions may include 
instances of “double counting”; a few FH centers have submitted a proportion of their 
variants to both the LOVD database (in the past) and ClinVar. While the exact number of 
these variants is presently unknown, efforts are underway to remove such cases. 
Secondly, the number of unique CNVs in LDLR (142; 100 deletions and 42 duplications) 
may be underestimated quite considerably. There have been 273 total CNV submissions, 
yet only 12 have defined breakpoints. This is a result of commonly applied detection 
methods such as MLPA (Wang, Ban, & Hegele, 2005), or more recently NGS depth of 
coverage analysis (Iacocca et al., 2017), which are limited to exon-level resolution. LDLR 
CNV submissions in ClinVar have thus largely been grouped by affected exon(s), but the 
likelihood of each breakpoint being identical in these “unique” CNV types is 
questionable. Previous breakpoint analysis has shown there are multiple unique CNV 
events which lead to the deletion of the 5’UTR–Exon 1 in LDLR (Hobbs et al., 1988) and 
the same may be true for other LDLR CNV types. 
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Only 10.7% of classified variants in LDLR have been considered as VUS by 
ClinVar submitters, compared to 55.2% and 39.9% VUS in APOB and PCSK9, 
respectively, suggesting potential pathogenicity is much more difficult to evaluate in 
APOB/PCSK9 compared to LDLR. Because a loss-of-function in LDLR is a known 
disease mechanism of FH, any clearly deleterious variant-type in LDLR can be 
considered pathogenic. However, only very specific variants in APOB and PCSK9 lead to 
FH. In PCSK9, causative variants must induce a gain of function in the encoded protein, 
and in APOB, causative variants must allow the production of the protein, but need to 
specifically alter the binding affinity to LDLR (known LDL binding domains are located 
within APOB exons 26 and 29). Generally, any null variant in these genes will lead to 
hypocholesterolemia, and thus are not expected to be identified in FH patients. This 
leaves most candidate APOB and PCSK9 variants missense or synonymous, which pose 
challenges to interpretation. Further, some APOB variants have been shown to have low 
penetrance, adding another level of difficulty in interpreting variants in this gene (Alves 
et al., 2014). Accordingly, it is unwarranted to confidently classify variants as pathogenic 
in APOB and PCSK9 without performing functional studies, leaving many of them as 
VUS. 
This effort has also revealed that many different variant classification methods are 
being used, which is problematic since non-standardization can lead to different 
interpretation of identical variants. Indeed, we saw 379 variants (~15% of variants in 
each gene) with conflicting classifications. Use of ACMG/AMP guidelines aims to 
achieve greater standardization and consistency in variant interpretation (Richards et al., 
2015). As we saw here, many FH research and diagnostic groups have adopted this new 
standard. However, the ACMG/AMP guidelines were designed to be generalizable to all 
Mendelian disorders, and ambiguities leave potential for differences in the application of 
various criteria among users, yielding inconsistent classifications. For instance, 114 
unique variants have conflicting classifications despite all submitters having cited the 
ACMG/AMP guidelines.  
 Beyond a degree of inherent subjectivity, the current ACMG/AMP guidelines do 
not adequately address FH. In a separate study, ACMG/AMP classification of a large 
subset of FH-associated variants resulted in a large proportion of VUS (42% in LDLR, as 
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well as 90% in APOB and 92% in PCSK9) (Chora et al., 2018). Cases of 
misclassifications when compared against known pathogenic/benign variants were also 
found. One of ClinGen’s key goals is the standardization of gene/disease-specific 
adjustments to the ACMG/AMP guidelines to address these issues, and to use these 
specified guidelines to provide a high level of confidence in ClinVar variant 
classifications.  
Current ClinVar submissions point to specific issues that need to be addressed 
imminently in order to further improve the interpretation of FH-associated variants. First, 
clinical details accompanying a submission need to have minimum standards. Many 
LDLR, APOB and PCSK9 variants were submitted without a disease association, 
rendering them of little value to interpretation efforts. Others were submitted with both 
hyper/hypocholesterolemia associations, and some had potentially incorrect disease 
associations – for example, deleterious/null variants in APOB/PCSK9 submitted with a 
disease association of FH.  
Second, richer supporting variant-level data must be submitted. Although FH 
centers successfully reported numerous variants, the same cannot be said concerning 
additional supporting variant-level data. Only eight variants had information about 
cosegregation, and patient phenotype descriptions were nearly nonexistent (e.g., no data 
on lipid profiles or cardiovascular disease). The large majority of submitters reported no 
functional studies for detected variants, although this is key to pathogenicity attribution, 
and are publicly available for more than 300 variants. The ACMG/AMP framework 
awards points to functional-level data, co-segregation data, normolipidemic data, and the 
number of observations/unrelated patients with each variant; if this information is kept 
stored in internal databases it will ultimately have a major negative impact on accurately 
interpreting ClinVar variants. Patient ethnicity would also be useful data, but was 
unreported. 
All submitters should include supporting variant-level data for retrospective and 
prospective variant submission. Ideally, submissions should include a short summary of 
phenotype and genetic testing results for each individual, such as untreated LDL-C, the 
genes tested, and any other variants detected in the patient's sample. As an illustrative 
case, consider a patient who presents with an LDL-C value typical of heterozygous FH 
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and has a candidate variant in both LDLR and APOB. If the LDLR variant is clearly 
pathogenic (suggested by previous aggregate evidence) then this case-level information 
adds evidence to support the APOB variant being benign (if no other evidence is available 
to suggest otherwise). When two such variants are submitted separately outside the 
testing context, others might interpret the APOB variant as a VUS or perhaps even as 
pathogenic if it is the only variant ascertained in their patient and see it has been 
previously reported on the database. Such contextual interpretation is undoubtedly 
performed internally by diagnostic laboratories but is currently not part of any variant 
submission process, despite it being readily accessible at the time of submission. 
Third, data submission needs to be ongoing. Although most of the world’s largest 
laboratory repositories for FH variants have now made submissions to ClinVar, a few 
important populations remain outstanding; including Italy, Denmark, Norway, Germany, 
Israel and Japan. Efforts are underway to encourage outstanding centers to submit their 
variants, and it is imperative this is achieved prior to the reclassification of all variants 
using FH-specified ACMG/AMP criteria to ensure diverse representation is accounted for 
in the specification of these criteria. Further, FH-associated variants are likely being 
identified on an exponential scale as NGS panels are becoming increasingly implemented 
in routine FH diagnosis, a trend sure to continue as sequencing costs continue to plummet 
and awareness of FH broadens. Thus, real-time submission of variant data must be a 
focus for all centers. 
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 Conclusion 
 
Efforts of data sharing, and reliable variant interpretation, are extremely important to 
improve the care of FH patients. Since FH is so prominent in the population, and as 
educational efforts continue, more health care/family physicians can be expected to order 
genetic testing. As such, FH-associated variant submissions to ClinVar are likely to 
continue to increase. This will also increase the use of ClinVar as an essential resource 
for variant interpretation, ultimately affecting patient management and cascade screening. 
The ClinGen FH VC-EP will continue to encourage data sharing and communication 
between clinical and research FH experts in order to improve variant interpretation and 
harmonize FH diagnosis across the world. 
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Chapter 5 – Discussion and conclusions 
5  
 Overview 
 
 
FH is a highly prevalent inherited dyslipidemia characterized by a lifelong exposure to 
elevated LDL-C levels with increased risk of premature atherosclerosis causing 
cardiovascular disease (Hegele, 1997). Despite the number of effective medications 
widely available, FH is severely underdiagnosed (<1% in most countries) and 
undertreated (Nordestgaard et al., 2013). 
 As molecular genetic technologies – namely next-generation sequencing - have 
become increasingly more affordable and available in recent years, FH has moved to the 
very forefront of precision medicine. Genetic testing has now become a central part of 
FH diagnosis globally. The are many important advantages in obtaining a genetic 
diagnosis of FH, which include: 1) achieving certainty in the context of incomplete 
clinical criteria, such as reduced prevalence of typical physical findings and/or 
unattainable or unreliable family history; 2) motivating cascade screening in family 
members, which markedly improves the rate of underdiagnosis and can be seen as a 
cornerstone of cardiovascular prevention; 3) directing specific therapeutic strategies for 
improved patient management; 4) to improve treatment compliance; and 5) to support 
insurance coverage of certain medications. 
 My thesis focused on improving the strategies used to provide genetic diagnosis 
of FH; this was approached in three main ways as discussed below. 
 
 
 Study findings and implications 
 
 
 In chapter 2, we investigated the potential for NGS data to be bioinformatically 
processed for the detection of CNVs in LDLR. In analysis of 388 FH patient samples, we 
found 100% concordance in LDLR CNV detection between MLPA - the gold standard or 
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reference standard method - and our new NGS approach. This demonstrated the ability of 
NGS with appropriate bioinformatics to identify both small and large-scale variants in a 
single platform and analytic procedure.  
 Accurate identification of LDLR CNVs from NGS data is important because this 
class of variation comprises a significant proportion of FH cases but not all sequencing 
facilities have the resources, time or interest to establish a parallel MLPA system for 
detecting them. Our cost for MLPA analysis in LDLR - including reagents, controls, 
duplicate analyses, and labor - was ~$110 CAD per patient sample, which totaled 
~$43,000 CAD for this cohort of 388 FH individuals. These costs are essentially 
eliminated when applying a bioinformatics method to NGS data; since such data are 
already being generated for small-scale variant analysis that precedes CNV assessment. 
We have found that once established, the bioinformatics workflow for CNV detection 
takes only an additional ~10 minutes for a set of 24 samples.  
 Because of the 100% sensitivity and specificity demonstrated by our method 
specifically, it can also be clinically reliable; this approach is now being implemented in 
the diagnosis of FH in Canada. Since our initial report in 2017, there have been 32 more 
LDLR CNVs identified in Canadian FH patients. Ultimately, transitioning to an NGS-
based approach for CNV analysis in LDLR will promote more widespread assessment of 
this important class of variation across diagnostic laboratories in the future. 
 In chapter 3 we performed CNV screening in additional FH-associated genes 
APOB, PCSK9, LDLRAP1, APOE, STAP1, LIPA, and ABCG5/8 in a cohort of 704 FH 
individuals using our newly demonstrated NGS bioinformatic method. Interestingly, we 
identified a whole-gene duplication of PCSK9 in two index cases, while we found no 
CNVs in APOB, LDLRAP1, APOE, STAP1, LIPA, or ABCG5/8. 
 CNVs in these seven genes had remained completely uninvestigated in FH; since 
collectively these genes are implicated in fewer than 10% of known monogenic FH cases, 
CNV analysis by traditional methods has been considered far too laborious and costly to 
perform, especially in large clinical cohorts. By using bioinformatic tools to evaluate 
existing targeted NGS data, surveying these genes for CNVs can now be considered 
economical. It is the goal of any diagnostic laboratory to account for all genetic 
abnormalities capable of explaining FH cases; this helps to avoid the possibility of false-
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negative genetic diagnoses. To this point, the two index cases who were positive for a 
causative PCSK9 duplication identified by this extended CNV screening, had previously 
no genetic aberrations to explain their phenotype, despite having genetic testing done in 
2014 and 2015, respectively. This finding also has therapeutic relevance, as elevated 
PCSK9 levels due to an increase in gene dosage may limit the efficacy of high-dose statin 
therapy and also PCSK9 inhibition. Indeed, the individuals under study with this PCSK9 
duplication had poor response to statin therapies and LDL-C target levels were 
unattainable, leaving them potentially exposed to continued progression of 
atherosclerosis. As demonstrated in index case A, increasing PCSK9 inhibition to a high 
dose was necessary for improved LDL-C management.  
In chapter 4, we took part in a large global collaboration effort to establish a 
centralized database of clinically-relevant genetic variants identified in FH patients. 
Together, this effort facilitated the submission of 5487 total and 2803 unique FH-
associated variants from 30 different centres in 13 countries, of which we contributed 369 
variants - the 4th largest single-center contribution.  
Prominent laboratories performing sequencing analysis of FH samples around the 
world have traditionally kept large numbers of variants and variant-level data in internal 
databases. This practice can lead to inconsistencies in the way two different laboratories 
interpret the same or similar variants; use of open-source data is essential for accurate and 
concordant variant classification (i.e. “pathogenic”; “unknown significance”; or 
“benign”). There is now an extensive range of FH-associated variants present on the 
ClinVar database to aid in interpretation efforts.  
Analysis of all 5908 total and 2883 unique FH-variant submissions presently on 
ClinVar has proven that there is little standardization in the methods and criteria used 
amongst laboratories to classify these variants. The ClinGen FH Variant Curation Expert 
Panel (FH VC-EP) has been working diligently over the past 2 years to establish a set of 
FH-specific variant classification guidelines, which adhere to the general ACMG/AMP 
framework. I have been fortunate enough to be involved with the collaborative 
discussions, drafting, and testing of these new FH-specific ACMG/AMP guidelines over 
the last two years, and have been signified as a co-first author for my contributions 
(manuscript currently in preparation). Establishment of these guidelines will help to 
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achieve a more evidence-based, standardized method for the classification of variants 
detected in FH patients; both retrospectively and prospectively. Following the approval of 
these guidelines by the ClinGen Clinical Domain Working Group Oversight Committee, 
we will use them to re-classify all 2883 unique FH-associated variants present on the 
ClinVar database. FH variant classifications which have been classified by these FH-
specified ACMG/AMP guidelines and approved by the ClinGen FH VC-EP will receive 
“3-star” status in the ClinVar database, which signifies Expert Panel-level confidence. As 
of December 5, 2018, ClinVar became the very first public database containing 
information about genes, variants, and their relationship to disease to be approved by the 
U.S. Food and Drug Administration (FDA). Specifically, “3-star” level variant 
classifications on ClinVar will now have an associated FDA tag, allowing them to be 
recognized as a source of valid scientific evidence that can be used to support clinical 
validity. This announcement has been considered an immense achievement for the 
ClinGen consortium due to its implications on further advancing the field of precision 
medicine.  
 
 
 Future directions 
 
Despite advancements in CNV screening and interpretation of DNA variants identified 
during the course of genetic testing, multiple aspects of FH diagnosis can be further 
improved. Most notably, ~20% of patients with a diagnosis of FH by clinical criteria have 
no identifiable genetic basis (monogenic or polygenic) to explain their phenotype; it is of 
interest to address this remaining “missing heritability”.  
 First, it is possible that rare causative variants exist in novel genes. Individuals 
with clear-cut “definite” FH (DFH; as diagnosed by Simon Broome or Dutch Lipid Clinic 
Network criteria; see Chapter 1 Table 1.1) but  no identifiable causal  variants in 
canonical FH-genes are prime candidates for discovery of novel FH-associated loci. 
Although, it is noteworthy that such an approach has been previously unavailing. Futema 
et al. (2014) performed whole-exome sequencing (WES) in a large cohort of 125 DFH 
patients negative for LDLR/APOB/PCSK9 variants but identified no putative FH-
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associated loci, suggesting that the genetic determinants in unexplained FH cases are 
likely to be highly heterogeneous, complicating the gene discovery process. Systematic 
study of larger DFH cohorts may be required, however, these are presumably difficult to 
acquire since 80% of DFH patients are found to be causative variant-positive by 
conventional screening in known FH-genes.  
 Second, increased availability of whole-genome sequencing (WGS) is likely to 
address the possibility that causative variants in non-coding regions, such as introns, exist 
in some FH individuals. The first example of this was reported by Reeskamp et al. in 
2018, who performed WGS in a large family with an unexplained autosomal dominant 
FH trait; they identified a novel single nucleotide variant (c.2140+103G>T) located deep 
within an intron of LDLR as the causal variant. The challenge with applying WGS to 
capture intronic and/or intergenic variation is that even when potential disease-causing 
variants are identified, they are often inherently difficult to interpret, at least in the 
absence of functional assays. Moreover, interpretation efforts are further compounded by 
the increased scale of variants likely to be identified, since intronic regions are generally 
variant-rich.  
Another potential non-coding element worthy of investigation are microRNAs 
(miRNAs), which are a class of short regulatory RNAs (20-24 nucleotides) known to 
modulate mRNA levels (Wagschal et al., 2015). At least four miRNAs (miR-128-1, miR-
148a, miR-130b, and mir-301b) have been predicted to regulate protein expression of 
LDLR, thus variation disrupting function in any one of these miRNAs may elicit a 
disease phenotype (Wagschal et al., 2015).  
Third, epigenetic modifications, which can impact gene expression, are a potential 
mechanism that may underlie high LDL-C in variant-negative FH patients. Methods such 
as sodium bisulfite sequencing (SBS) have been developed to detect epigenetic 
modifications, however, epigenetic changes are often cell-type specific (Huang, Jiang, & 
Zhang, 2014; Li & Tollefsbol, 2011). With the liver being the principal organ where 
epigenetic effects would be believed to impact LDL-C levels most significantly, SBS 
and/or gene expression analysis used to reveal epigenetic modifications causing high 
LDL-C may require a biopsy of these cells, which would be far too invasive, especially in 
the context of a diagnostic assay. 
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 Final conclusions 
 
 
Advances in FH diagnosis have been propagated by an improved understanding 
of the underlying genetic determinants together with substantially reduced costs 
associated with appropriate screening strategies. Here, we have demonstrated the 
applicability of NGS techniques to reliably detect CNVs in LDLR, and to further perform 
cost-effective CNV screening in additional FH-associated genes, expanding the ability to 
account for all genetic abnormalities capable of underlying FH cases. Lastly, to improve 
the interpretation of variants identified during genetic diagnosis, we have made a 
significant contribution to establishing a centralized publicly-available database, that will 
serve as an essential resource for harmonizing the interpretation of variants identified in 
FH patients worldwide.  
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